



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 15/203	A1	1) International Publication Number: WO 96/14323
		(43) International Publication Date: 17 May 1996 (17.05.96)

(21) International Application Number: PCT/US95/14686

(22) International Filing Date: 3 November 1995 (03.11.95)

(30) Priority Data:
08/335,278 7 November 1994 (07.11.94) US

(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).







(72) Inventors: NOVAK, Sarah, Tobin, Allen; 109 Castlewood Drive, Cary, NC 27511 (US). SOLL, Richard, Michael; 324 Glenn Avenue, Lawrenceville, NJ 08648 (US). ELLINGBOE, John, Watson; 117 John Street, Ridgewood, NJ 07450 (US). NGUYEN, Thomas, The; 509 West Ashdale Street, Philadelphia, PA 19120 (US).

(74) Agents: ALICE, Ronald, W.; American Home Products Corporation, Five Giralda Farms, Madison, NJ 07940-0874 (US) et al.

(81) Designated States: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).

Published*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: POLYANIONIC BENZYLGLYCOSIDES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION

**(57) Abstract**

This invention relates to the use of polyanionic benzylglycosides as smooth muscle cell proliferation inhibitors and as therapeutic compositions for treating diseases and conditions which are characterized by excessive smooth muscle proliferation, such as restenosis. The compounds of this invention are those of formula (I) wherein each of R¹, R², R³, and R⁴ are, independently, H, SO₃M, or (A); and each oligosaccharide group contains 1 to 3 sugar groups; M is lithium, sodium, potassium, or ammonium; n is 1 or 2; X is hydrogen, halogen, lower alkyl having 1 to 6 carbon atoms, or lower alkoxy having 1 to 6 carbon atoms; Y is carbonyl or sulfonyl; Z is alkyl having from 1 to 12 carbon atoms, (a), (b), (c), or (d); and X is as defined above; or a pharmaceutically acceptable salt thereof.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MD	Republic of Moldova	TJ	Tajikistan
DE	Germany	MG	Madagascar	TT	Trinidad and Tobago
DK	Denmark	ML	Mali	UA	Ukraine
ES	Spain	MN	Mongolia	US	United States of America
FI	Finland			UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

**POLYANIONIC BENZYLGLYCOSIDES AS INHIBITORS
OF SMOOTH MUSCLE CELL PROLIFERATION**

5 This invention relates to polyanionic benzylglycosides and their use as smooth muscle cell proliferation inhibitors and as therapeutic compositions for treating diseases and conditions which are characterized by excessive smooth muscle proliferation, such as restenosis.

Background of the Invention

10 All forms of vascular reconstruction such as angioplasty and vein bypass procedures effect a response to injury that ultimately leads to smooth muscle cell (SMC) proliferation and, subsequently, deposition of profuse amounts of extracellular matrix (Clowes, A. W.; Reidy, M. A. *J. Vasc. Surg* 1991, 13, 885). These events are
15 also central processes in the pathogenesis of atherosclerosis (Raines E. W.; Ross R. *Br. Heart J.* 1993, 69 (Supplement), S 30) as well as transplant arteriosclerosis (Isik, F. F.; McDonald, T. O.; Ferguson, M.; Yamanaka, E.; Gordon *Am. J. Pathol.* 1992, 141, 1139). In the case of restenosis following angioplasty, clinically relevant solutions for controlling SMC proliferation through pharmacological intervention
20 have remained elusive to date (Herrman, J. P. R.; Hermans, W. R. M.; Vos, J.; Serruys P. W. *Drugs* 1993, 4, 18 and 249). Any successful approach to selective SMC proliferation inhibition must not interfere with endothelial cell repair or the normal proliferation and function of other cells (Weissberg, P. L.; Grainger, D. J.; Shanahan C. M.; Metcalfe, J. C. *Cardiovascular Res.* 1993, 27, 1191). Indeed, an
25 important therapeutic consideration is to promote reendothelialization of the injured area concurrent with SMC proliferation inhibition (Casscells, W. *Circulation* 1992, 86, 722; Reidy, M. A.; Lidner, V. in *Endothelial Cell Dysfunctions*, Simionescu, N. and Simionescu M., Ed. Plenum Press, NY NY, (1992), 31).

30 The glycosaminoglycans heparin and heparan sulfate are endogenous inhibitors of SMC proliferation, yet are able to promote endothelial cell growth (Castellot, J. J. Jr.; Wright, T. C.; Karnovsky, M. J. *Seminars in Thrombosis and Hemostasis* 1987, 13, 489; Wight, T. N. *Arteriosclerosis* 1989, 9, 1). However, the
35 full clinical benefits of heparin, heparin fragments, chemically modified heparin, low molecular weight heparins, and other heparin mimicking anionic polysaccharides may be compromised due to other pharmacological liabilities (excessive bleeding arising

- 2 -

from anticoagulation effects, in particular) coupled with heterogeneity of the various preparations (Borman, S. *Chemical and Engineering News*, 1993, June 28, 27; Schmid, K. M.; Preisack, M.; Voelker, W.; Sujatta M.; Karsch, K. R. *Seminars in Thrombosis and Hemostasis* 1993, 19 (Suppl. 1), 155; Amann, F. W.;
5 Neuenschwander, C.; Meyer, B. *Seminars in Thrombosis and Hemostasis* 1993, 19 (Suppl. 1), 160; Radhakrishnamurthy, B.; Sharma, C.; Bhandaru, R. R.; Berenson, G. S.; Stanzani, L.; Mastacchi, R. *Atherosclerosis*, 1986 60, 141; Maffrand, J. P.; Hervert, M. M.; Bernat, A.; Defreyn, G.; Delevassee, D.; Savi, P.; Pinot, J. J.; Sampol, J. *Seminars in Thrombosis and Hemostasis*, 1991, 17 (Suppl. 2), 186). Since
10 the anticoagulant effects of many of these agents are independent of SMC antiproliferative activity, it would be expected that polyanionic agents which are more homogenous in composition and of more defined molecular structure would exhibit a more desirable profile with fewer side effects associated with the aforementioned
anionic polysaccharides.

15

Prior Art

WO 92/18546 discloses specific sequences of heparin, obtainable in pure form through synthesis or heparin fragment isolation, which exhibit SMC antiproliferation
20 activity. *Beta-Cyclodextrin tetradecasulfate* has been described as a smooth muscle cell proliferation inhibitor and as an effective inhibitor of restenosis (Weisz, P. B.; Hermann, H. C.; Joullie, M. M.; Kumor, K.; Levine, E. M.; Macarak, E. J.; Weiner, D. B. *Angiogenesis: Key Principle - Science - Technology - Medicine*- Steiner R., Weisz, P. B.; Langer, R. Eds. Birkhauser Verlag, Basel Switzerland, 1992, pg. 107;
25 Hermann, H. C.; Okada, S. S.; Hozakowska, E.; LeVeen, R. F.; Golden, M. A.; Tomaszewski J. E.; Weisz, P. B.; Barnathan E. S. *Arteriosclerosis and Thrombosis* 1993, 13, 924; Reilly, C. F.; Fujita, T.; McFall, R. C.; Stabilito, I. I.; Wai-si E.; Johnson, R. G. *Drug Development Research* 1993, 29, 137). U.S. Patent No. 5,019,562 discloses anionic derivatives of cyclodextrins for treating pathological
30 conditions associated with undesirable cell or tissue growth. WO 93/09790 discloses antiproliferative polyanionic derivatives of cyclodextrins bearing at least 2 anionic residues per carbohydrate residue. EP 312087 A2 and EP 312086 A2 discloses antithrombotic and anticoagulant properties of sulfated bis-aldoic acid amides.


U.S. Patents Nos. 4,431,636, 4,431,637, 4,431,638, and 4,435,387 describe polysulfated, thio- and oxy-aryl glycoside derivatives as modulators of the complement system.

5 The compounds of the present invention differ from all of the prior art in that the compounds (a) are benzylglycosides which bear no structural resemblance to heparin, sulfated cyclodextrins, or to sulfated lactobionic acid dimers, (b) contain no more than three contiguous sugar residues (trisaccharides) and (b) are of defined structure.

10

Description of the Invention


This invention describes the composition and utility of sulfated benzylglycosides of formula I




I

wherein

each of R¹, R², R³, and R⁴ are, independently, H, SO₃M, or a sugar group having the structure:



and each oligosaccharide group of the structure



contains from 1 to 3 sugar groups;

- 4 -


M is lithium, sodium, potassium, or ammonium;

n is 1 or 2;

X is hydrogen, halogen, lower alkyl having 1 to 6 carbon atoms, or lower alkoxy having 1 to 6 carbon atoms;

5 Y is carbonyl or sulfonyl;

Z is a group of formula $-(CH_2)_p-$, wherein p is an integer from 1 to 12;




and X is as defined above;
or a pharmaceutically acceptable salt thereof.

10 It is understood that each of the several occurrences of R^1 in any given molecule of Formula I herein may be the same or different. Similarly, each of the several occurrences of R^2 , R^3 or R^4 may be the same or different from the other occurrences of R^2 , R^3 or R^4 , respectively. Similarly, each of the several occurrences herein of Y in any given molecule and each of the occurrences herein of n in any
15 given molecule may be the same or different from any other occurrence of Y or n, respectively.

It is also understood that the lower alkyl groups herein may be straight chained or branched and may be, for example, methyl, ethyl, propyl, isopropyl or butyl groups. Similarly, the lower alkoxy groups herein may be straight chained or
20 branched and may be, for example, methoxy, ethoxy, propoxy, isopropoxy or butoxy groups.


A more preferred aspect or embodiment of this invention is the compounds of formula I:




I

5 wherein

each of R¹, R², R³, and R⁴ are, independently, H, SO₃M, or



and each oligosaccharide group of the structure





10 contains 1 or 2 sugar groups;

M is lithium, sodium, potassium, or ammonium;

n is 1 or 2; X is hydrogen, halogen, lower alkyl having 1 to 6 carbon atoms, or lower alkoxy having 1 to 6 carbon atoms;

Y is carbonyl or sulfonyl;

15 Z is alkyl having from 1 to 12 carbon atoms,



or a pharmaceutically acceptable salt thereof.

- 6 -

The most preferred compounds of this invention are:

- Dodecanedioic acid bis {[2-methyl-5-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)-phenyl]amide} tetradecasodium salt or a pharmaceutically acceptable salt thereof;
- 5 N,N'-Bis[5-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)-2-methylphenyl]-terephthalamide tetradecasodium salt or a pharmaceutically acceptable salt thereof;
- Biphenyl-4,4'-dicarboxylic acid bis {[5-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)-2-methylphenyl]amide} tetradecasodium salt or a pharmaceutically acceptable salt thereof;
- 10 N,N'-Bis[5-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)-2-methylphenyl]-isophthalamide tetradecasodium salt or a pharmaceutically acceptable salt thereof;
- Decanedioic acid bis {[3,5-bis(hepta-O-sulfato- β -D-cellobiosyloxymethyl)-phenyl]amide} octacosasodium salt or a pharmaceutically acceptable salt thereof;
- 15 Biphenyl-4,4'-dicarboxylic acid bis {[3,5-bis(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]amide} octacosasodium salt or a pharmaceutically acceptable salt thereof;
- 20 Biphenyl-4,4'-dicarboxylic acid bis {[3,5-bis-(hepta-O-sulfato- β -D-lactosyloxymethyl)phenyl]amide} octacosasodium salt or a pharmaceutically acceptable salt thereof;
- Biphenyl-4,4'-dicarboxylic acid bis {[3,5-(bis-(hepta-O-sulfato- β -D-maltosyloxymethyl)phenyl]amide} octacosasodium salt or a pharmaceutically acceptable salt thereof;
- 25 Biphenyl-4,4'-dicarboxylic acid bis {[3,5-bis-(tetra-O-sulfato- β -D-glucosyloxymethyl)phenyl]amide} hexadecasodium salt or a pharmaceutically acceptable salt thereof;


- 7 -

- Biphenyl-4,4'-dicarboxylic acid bis {[2-chloro-5-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]amide} tetradecasodium salt or a pharmaceutically acceptable salt thereof;
- 5 Biphenyl-4,4'-dicarboxylic acid bis {[4-chloro-2-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]amide} tetradecasodium salt or a pharmaceutically acceptable salt thereof;
- N,N'-Bis[3,5-bis-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]succinamide octacosasodium salt or a pharmaceutically acceptable salt thereof;
- 10 N,N'-Bis[3,5-bis(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]terephthalamide octacosasodium salt or a pharmaceutically acceptable salt thereof;
- Biphenyl-4,4'-disulfonic acid bis {[2-methyl-5-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]amide} tetradecasodium salt or a pharmaceutically acceptable salt thereof;
- 15 N,N'-Bis[2-methyl-5-(2,3,4,6-tetra-O-sulfato- β -D-glucopyranosyloxymethyl)phenyl]succinamide octasodium salt or a pharmaceutically acceptable salt thereof;
- 3,3'-[N,N'-Ureido]-bis{N-[2-methyl-5-(hepta-O-sulfato- β -D-maltosyloxymethyl)-phenyl]}benzamide tetradecasodium salt or a pharmaceutically acceptable salt thereof;
- 20 3,3'-(N,N'-Ureido)bis-((N-[2-chloro-5-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)-phenyl]}benzamide) tetradecasodium salt or a pharmaceutically acceptable salt thereof;
- 25 N,N'-Bis{3-[2-methyl-5-(hepta-O-sulfato- β -D-maltosyloxymethyl)phenyl]-carbamoyl}phenyl}isophthalamide tetradecasodium salt or a pharmaceutically acceptable salt thereof.

Process of the Invention

The compounds of the present invention are prepared according to the general sequence of reactions outlined in the Scheme below:

5



wherein R, n, X, Y, and Z are as defined above.

10 Thus, a glycosyl bromide 1 is coupled with a benzylic alcohol 2 in the presence of a catalyst such as a mercuric bromide, mercuric cyanide, silver triflate, or silver perchlorate in an aprotic solvent such as dichloromethane, ether, toluene, or nitromethane at temperatures ranging from -40°C to ambient temperature to yield glycoside 3. Reduction of the nitro group of 3 can be accomplished with a reducing agent such as stannous chloride in a polar aprotic solvent such as ethyl acetate at

15

- 9 -

ambient temperature to reflux, or by catalytic hydrogenation in the presence of a catalyst such as palladium on carbon gives an anilino compound 4. Coupling of 4 with a bis acid chloride or sulfonyl chloride ClY-Z-YCl can be done in the presence of an amine base such as triethylamine or diisopropylethylamine in an aprotic solvent such as dichloromethane or tetrahydrofuran, hydrolysis of any acetate groups present on the sugars with a base such as sodium methoxide in methanol or aqueous sodium hydroxide in methanol at ambient temperature to reflux, and sulfation of some or all of the free hydroxyl groups on the sugars can be completed with a reagent such as sulfur trioxide-trimethylamine complex or sulfur trioxide-pyridine complex in a polar aprotic solvent such as dimethylformamide or dimethylsulfoxide at temperatures ranging from 0°C to 100°C yields the target compounds I.

Alternatively, the sulfate groups can be introduced into compound 3 (after hydrolysis of any acetate groups). Sulfated compound 3 is then reduced to give sulfated 4 and coupled with ClY-Z-YCl to yield I.

This invention is also directed to pharmaceutical compositions, and the manufacture thereof, comprised of sulfated benzylglycosides either alone or in combination with excipients (i.e. pharmaceutically acceptable materials with no pharmacological effect). Such compositions are useful for diseases which are characterized by excessive smooth muscle cell proliferation, such as restinosis, most frequently arising from vascular reconstructive surgery and transplantation, for example, balloon angioplasty, vascular graft surgery, coronary artery bypass surgery, and heart transplantation. Other disease states in which there is unwanted vascular proliferation include hypertension, asthma, and congestive heart failure. The compounds of this invention are thus useful for treating these diseases and states.

The compounds of this invention may be administered systemically, for example by intravenous injection, typically ranging from 0.1 to 10 mg/kg/h over 5 - 30 days, or by subcutaneous injection at lower dose, by oral administration at higher dose than intravenous injection. Localized delivery of the compounds of this invention may also be achieved by transmembrane, transdermal, or other topical administrative routes using appropriate continuous release devices such as supporting matrix, where applicable. The compositions of the invention may be formulated with conventional excipients, such as a filler, a disintegrating agent, a binder, a lubricant, a flavoring agent and the like. These are formulated in a conventional manner. It is

- 10 -

understood that the compounds of this invention may be administered in any manner and at any concentration that is efficacious to the particular recipient. The manner of delivery and composition and concentration of the dose will be determined on an individual basis by the physician or other skilled medical professional treating the recipient.

Effects on Cell Proliferation

A. Cell Sources

10

The ability of the compounds of the present invention to inhibit smooth muscle cell proliferation and modulate endothelial cell growth was established using isolated aortic cells obtained from commercial sources or, for certain species, prepared in-house. Cell lines used in this study include human and porcine aortic smooth muscle cells and human aortic endothelial cells. Human aortic cell lines were obtained from Clonetics Corporation (San Diego).

15

Porcine aortas were received from a local slaughterhouse. The material was iced during transit. The aorta was scrupulously cleansed of fatty tissue and rinsed in sterile phosphate-buffered saline with 2% antibiotic / antimycotic (Gibco catalog # 20 600 - 5240 AG). The tissue was then digested in 10 - 15 mL of "Enzyme Mixture" containing collagenase type I, 165 U/mL; elastase type III, 15 U/mL; BSA, 2 mg/mL; and soybean trypsin inhibitor, 0.375 mg/mL followed by incubation at 37°C under 5% CO₂ for 10 - 15 min. After this treatment, the outer surface adventitia was easily 25 removed by peeling with forceps. The aorta was then longitudinally cut and laid open and the endothelial layer was removed by scraping.

25

The medial layer of cells was rinsed in enzyme solution, and placed in a new 100 mm dish with 10 mL of enzyme solution. The aorta was minced using a fine pair 30 of scissors and digested for 2 - 3 h at 37°C in 30 mL of fresh enzyme solution. After digestion, the tissue was homogenized using a sterile Pasteur pipette with a fire polished tip or an eppendorf pipetter with a 200 - 1000 mL sterile pipette tip. The suspension was then centrifuged for 10 min at 8000 rpm and the pellet was suspended in 4 - 6 mL of fresh medium and plated onto 4 - 6 100 mm flasks with vented caps. 35 Cells were allowed to grow to confluence and split using 0.25 % trypsin. Cells were evaluated for purity and overall quality using antibody to SMC actin.

B. Effects of compounds on cell proliferation using ³H Thymidine incorporation

5 Cells were assayed in early passage (generally passage 3 - 7) at sub-confluent conditions. Cultures were grown in 16 mm (24 well) multi-well culture dishes in media 199 supplemented with 10% fetal bovine serum and 2% antibiotic / antimycotic. At sub-confluence, the cells were placed in a defined serum free medium (AIM-V; Gibco) for 24 - 48 h prior to initiating the experimental protocol.

10 Although compounds were found to be more effective with longer pre-incubations, in general, experiments were initiated with the addition of compound, ³H thymidine and serum / growth factor to serum deprived synchronized cells and results are reported in this invention accordingly. Growth factor and serum stimulations
15 were optimized for each cell type.

 Compounds were added to each well at 50 fold dilution (20 μ L / well) and the plates were incubated for 24 - 36 h at 37°C in 5% CO₂. In this series, all compounds were found to be H₂O soluble and hence, test compounds were initially diluted in
20 H₂O and serially diluted into media. Compounds were routinely assayed at 1, 10, and 100 μ M. As a control, grade II porcine intestinal mucosal heparin (sodium salt) from Sigma (H-7005) was routinely assayed in all cell preparations at concentrations from 0.1 to 100 μ g/mL.

25 At the completion of the experiment, plates were placed on ice, washed three times with ice cold PBS and incubated in ice cold 10% trichloroacetic acid (TCA) for 30 min to remove acid soluble proteins. Solution was transferred to scintillation vials containing 0.4N HCl (500 μ L / vial to neutralize NaOH) and each well was rinsed
30 two times with water (500 μ L) for a total volume of 2 mL / vial.

 Data was obtained, in triplicate, for both control and experimental samples. Control (100%) data was obtained from maximally stimulated cells, as the result of growth factor or serum stimulation. Experimental data was obtained from cells maximally stimulated with growth factor or serum and treated with compound. Data
35 was expressed as a percent of control from which IC₅₀s could be determined. The compounds of the present invention are effective inhibitors of smooth muscle cell

- 12 -

proliferation as summarized in Table I. Furthermore, the compounds of the present invention exhibit human smooth muscle cell (HAOSMC) antiproliferative activity in the case where proliferation is driven by either 10% fetal bovine serum (FBS) or platelet derived growth factor (PDGF; human recombinant PDGF-AB purchased from
5 Upstate Biotechnology Inc., Lake Placid, NY). For example, the sulfated compound of Example 18 inhibits HAOSMC proliferation driven by FBS (IC₅₀ 200 nM) as well as by 5 ng/mL of PDGF (IC₅₀ 380 nM).

C. Effect on Endothelial Cell Growth vs. Smooth Muscle Cell Proliferation

10

The promotion of endothelial cell proliferation concurrent with inhibition of smooth muscle cell proliferation is an important consideration for inhibiting the exaggerated response to injury arising from vascular reconstruction. The compounds of the present invention enhance human endothelial cell growth driven by 2% FBS at
15 doses inhibitory towards human smooth muscle cell proliferation driven by 10% FBS as represented by the sulfated compound of Example 18 as shown in Figure 1.

D. Cytotoxicity:

20

Visually, all cells were found to tolerate high levels of all compounds quite well, however to insure that no toxicity was present, cytotoxicity of compounds was examined using a commercial modification of the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay. Briefly, cells were again grown in 24 well
25 plates to 70 - 80 % confluency and, as before, serum deprived for 24 - 48 h prior to initiation of the experimental protocol. To insure that the MTT assay monitored toxicity rather than proliferation, cells were incubated with 250 μM drug in fresh medium without serum for 24 h at 37°C in a humidified CO₂ incubator. Upon completion of the compound treatment, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
30 diphenyltetrazolium bromide) indicator dye was added for 4 h at 37°C. Cells were then lysed and aliquots from each well were transferred to a 96 well plate for analysis. Absorbance at 570 nm wavelength with a reference wavelength of 630 nm was recorded using an ELISA plate reader. Results are reported as percent viable using no drug (100% viable) and pre-solubilization (0% viable) standards. No toxicity was
35 observed up to 250 μM with sulfated compounds of Examples 10 - 25 and Example 26 (Step 5).

Anticoagulant Activity

5 The anticlotting activity of the compounds of this invention was evaluated in a partial thromboplastin time (APTT) assay using normal human plasma collected from 5 donors using the procedure of Fenichel et. al. (*Clin. Chem.* 1964, 10, 69). A BBL Fibrometer automatic precesion coagulation timer utilizing a 0.3 mL probe was employed. An Ellagic acid activated partial thromboplastin was used for these experiments. This reagent was added to human citrated plasma equilibrated at 37°C

10 in a plastic well in the clot timer. Calcium at 37°C was added, the clot timer was started and the time for fibrin clot formation (in seconds) was recorded. The effect of the compounds, added to plasma, over a concentration of 12.5 - 200 µg/mL was determined. Any plasma which did not clot after 240 seconds was assigned a clotting time of 240 seconds. An unfractionated heparin comparator was used over the

15 concentration range of 1.25 - 10 µg/mL. Clotting tests at all concentrations were run in triplicate. Analysis of variance for a randomized block design was used to determine the significance of differences observed in the clotting times. The potency is reported relative to heparin, wherein ratio >1 indicates weaker activity relative to heparin on a µg/mL comparison.

20

Table I

SULFATED COMPOUND OF EXAMPLE	Porcine Smooth Muscle Cell Antiproliferation IC ₅₀ or (% Inhibition at x concentration)	Anticoagulation Activity (APTT) Relative to Heparin
EXAMPLE 26, STEP 5	118 µM	nt
EXAMPLE 25	(8% inhibition at 50 µg/mL)	nt
EXAMPLE10	161 µM	nt

- 14 -

Table I Continued

SULFATED COMPOUND OF EXAMPLE	Porcine Smooth Muscle Cell Antiproliferation IC ₅₀ or (% Inhibition at x concentration)	Anticoagulation Activity (APTT) Relative to Heparin
EXAMPLE 24	58 μ M	nt
EXAMPLE 11	117 μ M	nt
EXAMPLE 12	72 μ M	nt
EXAMPLE 13	40.5 - 80 μ M	nt
EXAMPLE 14	3 μ M	6.7
EXAMPLE 15	4.7 μ M	2.0 - 2.3
EXAMPLE 20	45 μ M	nt
EXAMPLE 21	43 μ M	nt
EXAMPLE 22	5.2 - 22 μ M	2.0
EXAMPLE 16	3.6 μ M	2.2
EXAMPLE 17	23 - 50.8 μ M	insignificant activity at 50 μ g/mL
EXAMPLE 18	0.85 μ M	2.1

Table I Continued

SULFATED COMPOUND OF EXAMPLE	Porcine Smooth Muscle Cell Antiproliferation IC ₅₀ or (% Inhibition at x concentration)	Anticoagulation Activity (APTT) Relative to Heparin
EXAMPLE 19	(10 - 50% inhibition at 20 μM)	nt
EXAMPLE 23	9.5 - 40 μM	2.0
heparin (H-7005)	(45 - 83% inhibition at 50 μg/mL)	1

nt = not tested

- 5 Specific procedures are described in the following examples. These examples are given to illustrate the invention and should not be construed as limiting the invention set forth in the appended claims.

EXAMPLE 1

10

Step 1**5-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methyl-1-nitrobenzene**

15 To 4.0 g (24 mmol) of 4-methyl-3-nitrobenzyl alcohol and 20.0 g (29 mmol) of acetobromo-α-maltose in 60 mL of CH₃NO₂ was added 6.15 g (24 mmol) of Hg(CN)₂ and 6.91 g (19 mmol) of HgBr₂. After stirring at ambient temperature overnight, the reaction was quenched with sat. NaCl and was stirred for 20 min. The reaction mixture was extracted into CH₂Cl₂. The organic phase was washed with sat. NaCl, dried (MgSO₄) and flash chromatographed (1 : 2 and 1 : 1 EtOAc / petroleum ether). Rechromatography using ether / petroleum ether (3 : 1, then 4 : 1, then 100 : 0) gave 7.97 g of the title compound as a colorless solid: ¹H-NMR (CDCl₃, 300 MHz) δ 7.92 (s, 1 H), 7.41 (d, 1 H), 7.32 (d, 1 H), 5.42 (d, 1 H), 5.36 (t, 1 H), 5.25 (t, 1 H), 5.06 (t, 1 H), 4.8 - 5.0 (m, 3 H), 4.65 (d, 1 H), 4.62 (d, 1 H), 4.54 (dd, 1 H), 4.2 - 4.3 (m, 2 H), 3.9 - 4.1 (m, 3 H), 3.65- 3.71 (m, 1 H), 2.60 (s, 3 H), 2.16 (s, 3 H), 2.11 (s, 3 H), 2.04 (s, 3 H), 2.03 (s, 6 H), 2.01 (s, 3 H), and 2.00 ppm (s, 3 H).

20

25

- 16 -

Step 2**5-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenylamine**

Procedure A: A mixture of 4.0 g (5.09 mmol) of 5-(hepta-O-acetyl-β-D-maltosyl-oxymethyl)-2-methyl-1-nitrobenzene prepared in Example 1 and 8.00 g (35 mmol) of SnCl₂·H₂O in 100 mL EtOAc was heated at reflux for 2 h. The reaction mixture was cooled to room temperature and quenched with sat. NaHCO₃. After stirring for 15 min, the mixture was diluted with CH₂Cl₂ (200 mL) and filtered through solka floc (CH₂Cl₂). The organic phase was dried (MgSO₄) and concentrated. Flash chromatography (EtOAc / CH₂Cl₂, 1 : 5, then 1 : 4, then 1 : 2, then 1 : 1) gave 3.42 g (89% yield) of the title compound as a colorless foam: ¹H-NMR (CDCl₃, 300 MHz) δ 7.01 (d, 1 H), 6.63 (s, 1 H), 6.62 (d, 1 H), 5.41 (d, 1 H), 5.39 (t, 1 H), 5.20 (t, 1 H), 5.05 (t, 1 H), 4.82 - 4.90 (m, 2 H), 4.75 (d, 1 H), 4.54 (d, 1 H), 4.51 (d, 1 H), 4.26 (dd, 2 H), 3.95 - 4.01 (m, 3 H), 3.63 - 3.67 (m, 1 H), 2.17 (s, 6 H), 2.11 (s, 3 H), 2.03 (s, 6 H), 2.00 (s, 3 H), and 1.99 ppm (s, 6 H).

Procedure B: A solution of 31.1 g (39.6 mmol) of 5-(hepta-O-acetyl-β-D-maltosyl-oxymethyl)-2-methyl-1-nitrobenzene prepared in step 1 of Example 1 was hydrogenated at 50 psi over 10% Pd/C (10.0 g) for 1 h. The catalyst was removed by filtration and the filtrate was concentrated to give a white foam. Trituration with water gave 28.0 g (94%) of the title compound as a white solid, mp 154 - 156 °C.

EXAMPLE 2**Step 1****5-(Hepta-O-acetyl-β-D-cellobiosyloxymethyl)-2-methyl-1-nitrobenzene**

The title compound was prepared in 47% yield by the procedure of step 1 of Example 1 using 4-methyl-3-nitrobenzyl alcohol and acetobromocellobiose. Purification was achieved by flash chromatography (EtOAc / petroleum ether, 1 : 2 to 1 : 1 to 2 : 1): ¹H-NMR (CDCl₃, 300 MHz) δ 7.91 (s, 1 H), 7.40 (d, 1 H), 7.32 (d, 1 H), 4.80 - 5.20 (m, 6 H), 4.40 - 4.80 (m, 4 H), 4.36 (dd, 1 H), 4.02 - 4.13 (m, 2 H), 3.81 (t, 1 H), 3.60 - 3.68 (m, 2 H), 2.60 (s, 3 H), 2.14 (s, 3 H), 2.08 (s, 3 H), 2.06 (s, 3 H), 2.03 (s, 3 H), 2.02 (s, 3 H), 2.01 (s, 3 H), and 1.98 ppm (s, 3 H).

35

- 17

Step 2**5-(Hepta-O-acetyl-β-D-cellobiosyloxymethyl)-2-methylphenylamine**

The title compound, mp 180 - 182°C, was prepared in 62% yield from 5-
5 (hepta-O-acetyl-β-D-cellobiosyloxymethyl)-2-methyl-1-nitrobenzene using Procedure
A of step 2 of Example 1. Purification was achieved by flash chromatography
(EtOAc / petroleum ether, 1: 1 to 2 : 1): ¹H-NMR (DMSO-d₆, 400 MHz) δ 6.86 (d, 1
H), 6.48 (d, 1 H), 6.36 (dd, 1 H), 5.24 (t, 1 H), 5.10 (m, 1 H), 4.80 - 4.90 (m, 3 H),
4.61 - 4.72 (m, 2 H), 4.56 (d, 1 H), 4.30 - 4.31 (m, 2 H), 4.22 (dd, 1 H), 4.08 (dd, 1
10 H), 3.99 - 4.03 (m, 1 H), 3.94 (dd, 1 H), 3.73 - 3.81 (m, 2 H), 2.10 (s, 3 H), 2.10 (s, 3
H), 2.00 (s, 3 H), 1.98 (s, 3 H), 1.96 (s, 3 H), 1.95 (s, 3 H), 1.94 (s, 3 H), and 1.91
ppm (s, 1 H); mass spectrum (+FAB) *m/z* 778. Anal. Calcd. for C₃₄H₄₆NO₁₈: C,
53.97; H, 6.13; N, 1.85. Found: C, 53.67; H, 5.92; N, 1.62.

15

EXAMPLE 3**Step 1****5-(Hepta-O-acetyl-β-D-cellobiosyloxymethyl)-2-chloro-1-nitrobenzene**

The title compound was prepared in 45% yield by the procedure described in
20 step 1 of Example 1 using 4-chloro-3-nitrobenzyl alcohol and acetobromocellobiose:
¹H-NMR (CDCl₃, 300 MHz) δ 7.82 (d, 1 H), 7.53 (d, 1 H), 7.42 (dd, 1 H), 4.80 - 5.20
(m, 5 H), 4.73 (d, 1 H), 4.51 - 4.66 (m, 4 H), 4.30 - 4.40 (m, 1 H), 4.03 - 4.11 (m, 2
H), 3.81 (t, 1 H), 3.60 - 3.68 (m, 2 H), 2.13 (s, 3 H), 2.09 (s, 3 H), 2.06 (s, 3 H), 2.03
25 (s, 3 H), 2.01 (s, 3 H), 2.01 (s, 3 H), 1.99 (s, 3 H), and 1.57 ppm (s, 3 H).

Step 2**5-(Hepta-O-acetyl-β-D-cellobiosyloxymethyl)-2-chlorophenylamine**

The title compound was prepared from 5-(hepta-O-acetyl-β-D-cellobiosyl-
oxymethyl)-2-chloro-1-nitrobenzene in 61% yield as a solid by trituration with ether
using Procedure A of step 1 of Example 1: ¹H-NMR (CDCl₃, 300 MHz) δ 7.20 (d, 1
H), 6.75 (s, 1 H), 6.60 (d, 1 H), 4.89 - 5.19 (m, 5 H), 4.73 (d, 1 H), 4.47 - 4.60 (m, 4
H), 4.36 (dd, 1 H), 4.02 - 4.13 (m, 2 H), 3.80 (t, 1 H), 3.55 - 3.67 (m, 2 H), 2.14 (s, 3
35 H), 2.08 (s, 3 H), 2.03 (s, 3 H), 2.02 (s, 6 H), 2.01 (s, 3 H), and 2.00 ppm (s, 3 H).

- 18 -

EXAMPLE 4**Step 1****2-(Hepta-O-acetyl-β-D-cellobiosyloxymethyl)-4-chloro-1-nitrobenzene**

5

The title compound was prepared in 47% yield by the procedure of step 1 of Example 1 using 5-chloro-2-nitrobenzyl alcohol and acetobromocellobiose. Partial purification was achieved using flash chromatography (CH₂Cl₂ / EtOAc, 6 : 1) and the product used as is in the next reaction: ¹H-NMR (CDCl₃, 300 MHz) δ 8.09 (d, 1 H), 7.71 (d, 1 H), 7.43 (dd, 1 H), 4.90 - 5.25 (m, 8 H), 4.63 (d, 1 H), 4.52 (d, 1 H), 10 4.49 (d, 1 H), 4.38 (dd, 1 H), 4.03 - 4.16 (m, 3 H), 3.79 (t, 1 H), 3.60 - 3.68 (m, 2 H), 2.13 (s, 3 H), 2.10 (s, 6 H), 2.04 (s, 6 H), 2.01 (s, 3 H), and 1.98 ppm (s, 3 H).

Step 2**2-(Hepta-O-acetyl-β-D-cellobiosyloxymethyl)-4-chlorophenylamine**

15

The title compound was prepared in 55% yield from 2-(hepta-O-acetyl-β-D-cellobiosyloxymethyl)-5-chloro-1-nitrobenzene by Procedure A of step 2 of Example 1. Purification was achieved by trituration with ether: ¹H-NMR (CDCl₃, 300 MHz) δ 7.11 (dd, 1 H), 7.04 (d, 1 H), 6.65 (d, 1 H), 5.03 - 5.18 (m, 3 H), 4.88 - 4.97 (m, 2 H), 4.45 - 4.80 (m, 5 H), 4.36 (dd, 1 H), 4.02 - 4.13 (m, 2 H), 3.60 - 3.81 (m, 3 H), 20 2.16 (s, 3 H), 2.08 (s, 3 H), 2.04 (s, 3 H), 2.01 (s, 6 H), 2.00 (s, 3 H), and 1.98 ppm (s, 3 H).

25

EXAMPLE 5**Step 1****5-(Tetra-O-acetyl-β-D-glucopyranosyloxymethyl)-2-methyl-1-nitrobenzene**

30

The title compound was prepared in 54% yield by the procedure described in step 1 of Example 1 using α-D-glucopyranosyl bromide tetraacetate and 4-methyl-3-nitrobenzyl alcohol: ¹H-NMR (CDCl₃, 300 MHz) δ 7.92 (d, 1 H), 7.43 (dd, 1 H), 7.33 (d, 1 H), 5.06 - 5.24 (m, 3 H), 4.92 (d, 1 H), 4.66 (d, 1 H), 4.59 (d, 1 H), 4.28 (dd, 1 H), 4.18 (dd, 1 H), 3.68 - 3.72 (m, 1 H), 2.60 (s, 3 H), 2.11 (s, 3 H), 2.07 (s, 3 H), 35 2.03 (s, 3 H), and 2.01 ppm (s, 3 H).

- 19 -

Step 2**5-(Tetra-O-acetyl- β -D-glucopyranosyloxymethyl)-2-methylphenylamine**

The title compound was prepared in 63% yield by Procedure A of step 2 of Example 1 from 5-(tetra-O-acetyl- β -D-glucopyranosyloxymethyl)-2-methyl-nitrobenzene and purified by trituration of the crude reaction mixture with ether: ¹H-NMR (CDCl₃, 300 MHz) δ 7.02 (d, 1 H), 6.64 (s, 1 H), 6.63 (d, 1 H), 5.02 - 5.17 (m, 3 H), 4.79 (d, 1 H), 4.50 - 4.55 (m, 2 H), 4.29 (dd, 1 H), 4.17 (dd, 1 H), 3.64 - 3.68 (m, 1 H), 2.18 (s, 3 H), 2.11 (s, 3 H), 2.02 (s, 3 H), 2.01 (s, 3 H), and 2.00 ppm (s, 3 H).

EXAMPLE 6**Step 1****3, 5-Bis(hepta-O-acetyl- β -D-cellobiosyloxymethyl)-1-nitrobenzene**

The title compound was prepared in 42% yield by the procedure described in step 1 of Example 1 using one equivalent of 5-nitro-m-xylene- α,α' -diol, two equivalents of acetobromocellobiose, and two equivalents of all other reagents. Purification was achieved by flash chromatography (EtOAc / CH₂Cl₂, 3 : 1) and trituration with ether: ¹H-NMR (CDCl₃, 300 MHz) δ 8.10 (s, 2 H), 7.48 (s, 1 H), 4.88 - 5.30 (m, 12 H), 4.68 (d, 2 H), 4.52 - 4.59 (m, 6 H), 4.38 (dd, 2 H), 4.00 - 4.13 (m, 4 H), 3.82 (t, 2 H), 3.58 - 3.68 (m, 4 H), 2.13 (s, 6 H), 2.08 (s, 6 H), 2.07 (s, 6 H), 2.03 (s, 12 H), 2.01 (s, 6 H), and 1.98 ppm (s, 6 H).

Step 2**3, 5-Bis(hepta-O-acetyl- β -D-cellobiosyloxymethyl)phenylamine**

The title compound was prepared in 54% yield by Procedure A of step 2 of Example 1 using 3,5-bis(hepta-O-acetyl- β -D-cellobiosyloxymethyl)-1-nitrobenzene. Purification was achieved by flash chromatography (EtOAc / petroleum ether, 1 : 1): ¹H-NMR (CDCl₃, 300 MHz) δ 6.73 (bs, 2 H), 6.67 (bs, 1 H), 5.03 - 5.30 (m, 6 H), 4.97 (d, 2 H), 4.91 (d, 2 H), 4.75 (d, 2 H), 4.49 - 4.61 (m, 6 H), 4.37 (dd, 2 H), 4.02 - 4.13 (m, 6 H), 3.81 (t, 2 H), 3.57 - 3.69 (m, 4 H), 2.15 (s, 6 H), 2.08 (s, 6 H), 2.03 (s, 6 H), 2.01 (s, 18 H), and 1.98 ppm (s, 6 H).

- 20 -

EXAMPLE 7**Step 1****3, 5-Bis(hepta-O-acetyl- β -D-lactosyloxymethyl)-1-nitrobenzene**

5

The title compound was prepared by the procedure described in step 1 of Example 1 using 1 equivalent of 5-nitro-m-xylene- α,α' -diol, two equivalents of acetobromolactose, and two equivalents of all other reagents. Purification was achieved initially by flash chromatography (EtOAc / CH₂Cl₂ (3 : 1)) and then
10 rechromatography first with toluene / EtOAc (1 : 1) and then with EtOAc / CH₂Cl₂ (1 : 4 to 1 : 2) to give partially pure product which was used directly in the next reaction.

Step 2**3, 5-Bis(hepta-O-acetyl- β -D-lactosyloxymethyl)phenylamine**

15

The title compound was prepared by procedure A of step 2 of Example 1 using 3,5-bis(hepta-O-acetyl- β -D-lactosyloxymethyl)-1-nitrobenzene. Partial purification was achieved by flash chromatography (CH₂Cl₂ / EtOAc (2 : 1 to 1 : 2)) and then rechromatography (CH₂Cl₂ / EtOAc (3 : 1 to 1 : 1)) to give the title
20 compound.

EXAMPLE 8**Step 1**

25

3, 5-Bis(tetra-O-acetyl- β -D-glucosyloxymethyl)-1-nitrobenzene

The title compound was prepared by the procedure described in step 1 of Example 1 using 1 equivalent of 5-nitro-m-xylene- α,α' -diol, two equivalents of acetobromoglucose, and two equivalents of all other reagents. Purification was
30 achieved by flash chromatography (EtOAc / CH₂Cl₂ (1 : 4 to 1 : 2) to give a 29% yield of nearly pure title compound which was used without further purification.

- 21 -

Step 2**3, 5-Bis(tetra-O-acetyl- β -D-glucosyloxymethyl)phenylamine**

The title compound was prepared by procedure A of step 2 of Example 1 using 6.27 g of 3, 5-bis-(tetra-O-acetyl- β -D-glucosyloxymethyl)-1-nitrobenzene. Purification was achieved by flash chromatography (CH₂Cl₂ / EtOAc (3 : 2)) to give 2.00 g (39% yield) of the title compound as a yellow oil: partial ¹H-NMR (CDCl₃, 300 MHz) δ 6.56 (s, 3 H), 5.0 - 5.2 (m, 6 H), 4.8 (d, 2 H), 4.4 - 4.6 (m, 4 H), 3.7 ppm (brd, 2 H).

10

EXAMPLE 9**Step 1****3, 5-Bis(hepta-O-acetyl- β -D-maltosyloxymethyl)-1-nitrobenzene**

15

The title compound was prepared by the procedure described in step 1 of Example 1 using 2.57 g (14.02 mmol; 1 equivalent) of 5-nitro-m-xylene- α,α' -diol, two equivalents of acetobromomaltose, and two equivalents of all other reagents, all in CH₃NO₂ (200 mL). Purification was achieved by flash chromatography (EtOAc / CH₂Cl₂ (1 : 2 to 1 : 1). Rechromatography (Et₂O) gave 11.4 g (57% yield) of the title compound which was used in the next reaction: partial ¹H-NMR (CDCl₃, 300 MHz) δ 8.11 (s, 2 H), 7.49 (s, 1 H), 5.42 (d, 2 H), 5.36 (t, 2 H), 5.26 (t, 2 H), 5.06 (t, 2 H), 4.21 - 4.29 (m, 4 H), and 3.69 - 3.72 ppm (m, 2 H).

20

Step 2**3, 5-Bis(hepta-O-acetyl- β -D-maltosyloxymethyl)phenylamine**

The title compound was prepared by procedure A of step 2 of Example 1 using 3,5-bis(hepta-O-acetyl- β -D-maltosyloxymethyl)-1-nitrobenzene. Purification was achieved by flash chromatography (CH₂Cl₂ / EtOAc (1 : 1)) to give 4.43 g (40% yield) of the title compound: partial ¹H-NMR (CDCl₃, 300 MHz) δ 6.57 (s, 3 H), 5.41 (d, 2 H), 5.36 (t, 2 H), 5.23 (t, 2 H), 5.50 (t, 2 H), 4.75 (d, 2 H), 4.26 (m, 4 H), and 3.65 - 3.69 ppm (m, 2 H).

25

30

- 22 -

EXAMPLE 10**Step 1****Dodecanedioic Acid Bis{[5-(β-D-cellobiosyloxymethyl)-2-methylphenyl]amide}**

5

To a solution of 5-(hepta-O-acetyl-β-D-cellobiosyloxymethyl)-2-methyl-phenylamine (1.03 g, 1.36 mmol) and triethylamine (189 μL, 1.36 mmol) in THF (15 mL) was added dodecanedioyl dichloride (170 μL, 0.681 mmol). After stirring at room temperature for 2 h, the reaction mixture was quenched with MeOH, diluted with CH₂Cl₂, and then washed with water. The organic phase was dried (MgSO₄), filtered, and concentrated to give 1.157 g of a colorless solid. This product was dissolved in MeOH (25 mL) and was treated with 11.9 mL (11.9 mmol) of 1 N NaOH. After stirring at 50°C for 5 h, the reaction mixture was cooled to room temperature and treated with 9.5 mL (9.5 mmol) of 1 N HCl. Collection of the colorless solid provided the title compound (566 mg, 75% yield), mp >200°C: partial ¹H (DMSO-d₆, 400 MHz) δ 9.25 (s, 2 H), 7.32 (s, 2 H), 7.16 (d, 2 H), 7.10 (d, 1 H), 4.77 (d, 2 H), 4.50 (d, 2 H), 4.24 - 4.30 (two doublets, 2 H), 3.78 (d, 2 H), 3.69 (d, 2 H), 3.63 (br d, 2 H), 2.99 (t, 2 H), 2.30 (t, 4 H), 1.58 (br t, 4 H), and 1.29 ppm (br s, 12 H); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 171.1, 136.2, 135.5, 131.1, 130.0, 124.8, 103.2, 101.7, 80.6, 76.8, 76.4, 75.0, 74.9, 73.3, 73.1, 70.0, 69.5, 61.0, 60.4, 35.7, 28.9, 28.8, 28.7, 25.3, and 17.6 ppm; mass spectrum (-FAB) *m/z* 1115 (M-H); IR (KBr) 3430 and 1660 cm⁻¹. Anal. Calcd. for C₅₂H₈₀N₂O₂₄•4 H₂O: C, 52.51; H, 7.46; N, 2.36. Found: C, 52.53; H, 7.28; N, 2.27.

25

Step 2**Dodecanedioic Acid Bis{[2-methyl-5-(hepta-O-sulfato-β-D-cellobiosyloxymethyl)phenyl]amide} Tetradesodium Salt**

A solution of dodecanedioic acid bis{[5-(β-D-cellobiosyloxymethyl)-2-methyl-phenyl]amide} (391 mg, 0.350 mmol) and sulfur trioxide trimethylamine complex (3.66 g, 26.3 mmol) in DMF (40 mL) was heated at 70°C for 3 days. The reaction mixture was concentrated *in vacuo* and passed through a Sephadex G-10 column (twice). Cation exchange was effected using a Dowex 50 x 8 strongly acidic (Na form) column to give 433 mg of the title compound: partial ¹H-NMR (D₂O, 400 MHz) δ 7.39 (d, 2 H), 7.36 (d, 2 H), 7.29 (s, 2 H), 4.94 (d, 2 H), 4.80 - 4.90 (m, 4 H), 4.59 (dd, 2 H), 2.49 (t, 4 H), 2.23 (s, 3 H), 2.30 - 2.40 (m, 4 H), and 1.30 - 1.50 ppm

35

- 23 -

(m, 12 H); ^{13}C -NMR (D_2O , 100 MHz) δ 176.8, 135.2, 134.9, 134.4, 130.9, 127.8, 127.1, 100.0, 99.1, 77.7, 77.4, 77.1, 74.4, 73.7, 73.5, 73.1, 70.7, 67.7, 66.6, 35.8, 28.5, 28.3, 25.5, and 16.9 ppm; mass spectrum (negative electrospray) (m - z Na)/ z 825.6 (M-3Na) $^{3-}$, 613.5 (M-4Na) $^{4-}$, and 486.2 (M-5Na) $^{5-}$. Anal. Calcd. for $\text{C}_{52}\text{H}_{66}\text{N}_2\text{O}_{66}\text{S}_{14}\text{Na}_{14}\cdot 14\text{H}_2\text{O}$: C, 17.83; H, 2.70; N, 0.80; S, 17.40. Found: C, 17.96; H, 2.57; N, 0.72; S, 17.11.

EXAMPLE 11

10

Step 1

N,N'-Bis[5-(β -cellobiosyloxymethyl)-2-methylphenyl]terephthalamide

To 813 mg (1.08 mmol) of 5-(hepta-O-acetyl- β -D-cellobiosyloxymethyl)-2-methylphenylamine in THF (20 mL) containing triethylamine (148 μL , 1.08 mmol) was added terephthaloyl chloride (109 mg, 0.538 mmol). After stirring at ambient temperature for 2 h, the reaction mixture was quenched with MeOH, diluted with CH_2Cl_2 and washed with water. Drying (MgSO_4) and concentration gave crude product, which was diluted with MeOH (25 mL) and treated with 8.7 mL (8.7 mmol) of 1 N NaOH. After stirring at 50°C for 3 h, the suspension was filtered to provide 512 mg (89%) yield of the title compound as a colorless solid, mp >210°C: ^1H (DMSO- d_6 ; 400 MHz) δ 10.07 (s, 2 H), 8.10 (s, 4 H), 7.35 (s, 2 H), 7.26 (d, 2 H), 7.22 (d, 2 H), 5.22 - 5.24 (m, 4 H), 5.01 (d, 2 H), 4.99 (d, 2 H), 4.82 (d, 2 H), 4.68 (d, 2 H), 4.54 - 4.64 (m, 6 H), 4.32 (d, 2 H), 4.25 (d, 2 H), 3.75 - 3.80 (d, 2 H), 3.63 - 3.77 (m, 4 H), 3.37 - 3.41 (m, 2 H), 2.97 - 3.19 (m, 10 H), and 2.23 ppm (s, 6 H); ^{13}C -NMR (DMSO- d_6 ; 100 MHz) δ 164.6, 137.0, 136.0, 135.9, 133.0, 130.1, 127.7, 126.0, 125.6, 103.2, 101.8, 80.6, 76.8, 76.4, 75.1, 74.9, 73.3, 73.2, 70.0, 69.3, 61.0, 60.4, and 17.7 ppm; mass spectrum m/z 1052, 889, and 725. Anal. Calcd. for $\text{C}_{48}\text{H}_{64}\text{N}_2\text{O}_{24}$: C, 54.75; H, 6.13; N, 2.66. Found: C, 55.54, H, 6.33; N, 2.57.

30

- 24 -

Step 2**N,N'-Bis[5-(hepta-O-sulfato-β-D-cellobiosyloxymethyl)-2-methylphenyl]terephthalamide TetradecaSodium Salt**

5 A mixture of N,N'-bis[5-(β-cellobiosyloxymethyl)-2-methylphenyl]-terephthalamide (321 mg, 0.305 mmol) and sulfur trioxide trimethylamine complex (3.06 g, 22.0 mmol) in DMF (25 mL) was stirred at 70°C for 4 days. The reaction mixture was concentrated and passed through a Sephadex G-10 column. ¹H-NMR analysis showed incomplete sulfation. The product was resubmitted to sulfation with
10 3.06 g (22.0 mmol) of sulfur trioxide trimethylamine complex in 25 mL of DMF at 70°C for 5 days. The reaction mixture was cooled to ambient temperature, concentrated *in vacuo*, and passed through a Sephadex G-10 column. Cation exchange using a Dowex column (50 x 8; strongly acidic; Na form) provided 469 mg (62% yield) of the title compound, mp 178 °C (dec): partial ¹H-NMR (D₂O; 400
15 MHz) δ 8.11 (s, 4 H), 7.40 - 7.50 (m, 6 H), 4.98 (d, 2 H), 4.95 (d, 2 H), and 2.32 ppm (s, 6 H); ¹³C-NMR (D₂O; 100 MHz) δ 169.5, 136.9, 135.4, 135.2, 134.3, 131.0, 128.1, 128.0, 127.0, 100.0, 99.1, 77.7, 77.4, 77.3, 77.1, 74.4, 73.7, 73.4, 73.1, 70.7, 67.7, 66.7, and 16.8 ppm. Anal. Calcd. for C₄₈H₅₀N₂O₆₆S₁₄Na₁₄•10 H₂O: C, 20.58; H, 2.51; N, 1.00; S, 17.17. Found: C, 20.21; H, 2.84; N, 0.96; S, 17.34.

20

EXAMPLE 12**Step 1****Biphenyl-4,4'-dicarboxylic Acid Bis{[5-(β-D-cellobiosyloxymethyl)-2-methylphenyl]amide}**

25

To a solution of 887 mg (1.18 mmol) of 5-(hepta-O-acetyl-β-D-cellobiosyloxymethyl)-2-methylphenylamine and 162 μL (1.18 mmol) of triethylamine in THF (20 mL) was added 164 mg (0.588 mmol) of biphenyl 4,4'-dicarboxylic acid chloride.
30 After stirring at room temperature for 4 h, the reaction mixture was quenched with MeOH, diluted with CH₂Cl₂ and washed with water. The organic phase was dried (MgSO₄), filtered, and concentrated to a colorless solid (1.01 g). A solution of the crude material (985 mg, 0.574 mmol) in MeOH (25 mL) containing 9.18 mL (9.18 mmol) of 1 N NaOH was stirred for 3 h at 50°C. The reaction mixture was cooled,
35 and title compound was collected as a white powder (444 mg, 69% yield): partial ¹H-NMR (DMSO-d₆; 300 MHz) δ 10.01 (s, 2 H), 8.13 (d, 4 H), 7.94 (d, 4 H), 7.37 (s, 2

- 25 -

H), 7.28 (d, 2 H), 7.23 (d, 2 H), 5.24 (d, 2 H), 5.00 (q, 2 H), 4.84 (d, 2 H), 4.56 - 4.69 (m, 4 H), 4.33 (d, 2 H), 4.27 (d, 2 H), and 2.25 ppm (s, 3 H).

Step 2

5 **Biphenyl-4,4'-dicarboxylic Acid Bis([5-(hepta-O-sulfato-β-D-cellobiosyloxymethyl)-2-methylphenyl]amide) Tetradecasodium Salt**

A solution of 437 mg (0.387 mmol) of biphenyl-4,4'-dicarboxylic acid bis([5-β-D-cellobiosyloxymethyl)-2-methylphenyl]amide) and 3.85 g (27.7 mmol) of sulfur trioxide trimethylamine complex in DMF (25 mL) was stirred at 70°C for 5 days. The reaction mixture was quenched with water and concentrated *in vacuo*. The residue was dissolved in a small amount of water and passed through a Sephadex G-10 column. Cation exchange was accomplished using Dowex 50 x 8 strongly acidic (Na form) resin to provide, after azeotropic drying with toluene, 742 mg (75% yield) of the title compound, mp 170°C (dec): partial ¹H-NMR (D₂O; 400 MHz) δ 8.09 (d, 4 H), 7.97 (d, 4 H), 7.40 (m, 6 H), 4.98 (d, 2 H), 4.94 (d, 2 H), 4.63 - 4.68 (m, 4 H), 4.56 (dd, 2 H), 4.41 (dd, 2 H), 4.30 - 4.37 (m, 6 H), 4.17 - 4.23 (m, 4 H), 3.99 - 4.05 (m, 4 H), and 2.31 ppm (s, 6 H); ¹³C-NMR (D₂O; 100 MHz) δ 169.7, 143.2, 135.3, 135.2, 134.4, 132.8, 130.9, 128.1, 128.0, 127.4, 127.0, 99.9, 98.9, 77.6, 77.3, 77.2, 77.0, 74.2, 73.6, 73.3, 73.0, 70.6, 67.6, 66.6, and 16.7 ppm. Anal. Calcd. for C₅₉H₅₄N₂O₆₆S₁₄Na₁₄•14 H₂O: C, 21.97; H, 2.80; N, 0.95; S, 16.29. Found: C, 21.77; H, 2.90; N, 0.95; S, 13.66.

EXAMPLE 13

25

Step 1

N,N'-Bis[5-(β-D-cellobiosyloxymethyl)-2-methylphenyl]isophthalamide

To a solution of 887 mg (1.18 mmol) of 5-(hepta-O-acetyl-β-D-cellobiosyloxymethyl)-2-methylphenylamine in THF (20 mL) containing triethylamine (162 μL, 1.18 mmol) was added isophthaloyl dichloride (119 mg, 0.587 mmol). After stirring at ambient temperature for 2 h, the reaction mixture was quenched with MeOH, diluted with CH₂Cl₂, and washed with water. The organic phase was dried (MgSO₄) and concentrated to give 1.00 g of a colorless solid. A solution of the crude product in MeOH (25 mL) containing 9.76 mL (9.76 mmol) of 1 N NaOH was stirred at 50°C

- 26 -

for 3 h. The resulting solid was collected and azeotropically dried over toluene to give 355 mg (55% yield) of the title compound as a colorless powder, mp 200-203°C: partial $^1\text{H-NMR}$ (DMSO-d_6 ; 400 MHz) δ 10.09 (s, 2 H), 8.54 (s, 1 H), 8.15 (d, 2 H), 7.68 (t, 1 H), 7.34 (s, 2 H), 7.26 (d, 2 H), 7.21 (d, 2 H), 5.24 (t, 4 H), 5.01 (dd, 2 H),
5 4.82 (d, 2 H), 4.69 (s, 2 H), 4.54 - 4.69 (m, 4 H), 4.32 (d, 2 H), 4.25 (d, 2 H), 3.76 - 3.80 (m, 2 H), 3.63 - 3.69 (m, 4 H), and 2.24 ppm (s, 6 H); $^{13}\text{C-NMR}$ (DMSO-d_6 ; 100 MHz) δ 164.9, 136.1, 135.9, 134.8, 133.0, 130.5, 130.1, 128.6, 127.1, 125.9, 125.6, 103.2, 101.8, 80.6, 76.8, 76.4, 75.1, 74.9, 73.3, 73.2, 70.0, 69.4, 61.0, 60.4, and 17.7 ppm; mass spectrum (-FAB) m/z 1051, 727, and 889. Anal. Calcd. for
10 $\text{C}_{48}\text{H}_{64}\text{N}_2\text{O}_{24}\cdot 3\text{H}_2\text{O}$: C, 52.08; H, 6.37; N, 2.53. Found: C, 51.89; H, 6.31; N, 2.26.

Step 2

N,N'-Bis[5-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)-2-methylphenyllisophthalamide Tetradecasodium Salt

15

A solution of N,N'-bis[5-(β -D-cellobiosyloxymethyl)-2-methylphenyl]-isophthalamide (180 mg, 0.171 mmol) and 1.79 g (11.98 mmol) of sulfur trioxide trimethylamine complex in DMF (25 mL) was stirred at 70°C for 4 days. The
20 reaction mixture was concentrated and then purified using a Sephadex G-10 column with water elution. Cation exchange was effected with a column of Dowex 50 x 8 strongly acidic (Na form) resin with water elution. Removal of water *in vacuo* and azeotropic drying with toluene gave 358 mg (84% yield) of the title compound as a colorless solid, mp 171 °C (dec): partial $^1\text{H-NMR}$ (D_2O ; 400 MHz) δ 8.43 (s, 2 H),
25 8.21 (dd, 2 H), 7.78 (t, 1 H), 7.40 - 7.50 (m, 6 H), 4.97 (d, 2 H), 4.94 (d, 2 H), 4.56 (dd, 2 H), and 2.30 ppm (s, 6 H); $^{13}\text{C-NMR}$ (D_2O ; 100 MHz) δ 169.2, 135.3, 135.1, 134.3, 134.0, 131.0, 130.9, 129.3, 128.0, 126.9, 126.5, 99.9, 99.0, 135.5, 77.3, 77.2, 77.0, 74.3, 73.6, 73.3, 73.0, 70.6, 67.6, 66.6, and 16.7 ppm. Anal. Calcd. for
30 $\text{C}_{48}\text{H}_{50}\text{N}_2\text{O}_{66}\text{S}_{14}\text{Na}_{14}\cdot 14\text{H}_2\text{O}\cdot \text{Na}_2\text{SO}_4$: C, 19.12, H, 2.61; N, 0.93; S, 17.01. Found: C, 18.97; H, 2.45; N, 0.94; S, 15.68.

- 27 -

EXAMPLE 14**Step 1****Decanedioic Acid Bis{[3,5-bis(β -D-cellobiosyloxymethyl)phenyl]amide}**

5

To a solution of 3, 5-bis(hepta-O-acetyl- β -D-cellobiosyloxymethyl)-phenylamine (817 mg, 0.588 mmol) and triethylamine (82 μ L, 0.59 mmol) in THF (25 mL) was added 74 μ L (0.295 mmol) of dodecanedioyl dichloride. The reaction mixture was stirred at ambient temperature for 90 min, quenched with MeOH, diluted with CH₂Cl₂, and washed with water. The organic phase was dried (MgSO₄) and concentrated to a colorless solid (834 mg, 95% yield). The crude product was dissolved in MeOH (25 mL) and was treated with 8.4 mL (8.4 mmol) of 1 N NaOH. After stirring at 50°C for 2 h, the reaction mixture was quenched at room temperature with 7.84 mL of 1 N HCl, concentrated, and purified by reverse phase column chromatography (RP silica 60) using MeOH / H₂O (1 : 1) elution. Rechromatography using MeOH / H₂O (2 : 3) provided 438 mg (87% yield) of the title compound as a colorless solid: partial ¹H-NMR (D₂O; 400 MHz) δ 7.45 (s, 4 H), 7.26 (s, 2 H), 4.64 (d, 4 H), 4.47 (t, 8 H), 3.80 (dd, 4 H), 3.71 (dd, 4 H), 2.30 (br t, 4 H), 1.55 (t, 4 H), and 1.17 ppm (br m, 12 H); ¹³C-NMR (D₂O; 100 MHz) δ 175.1, 138.1, 137.7, 124.4, 120.3, 102.5, 101.3, 78.7, 75.9, 75.5, 74.7, 74.3, 73.1, 72.8, 70.8, 69.4, 60.5, 60.0, 36.6, 28.7, 28.6, 28.5, and 25.3 ppm. Anal. Calcd. for C₇₆H₁₂₀H₂O₄₆•10 H₂O: C, 46.15; H, 7.13; N, 1.42. Found: C, 45.91; H, 6.82; N, 1.41.

10

15

20

Step 2**Decanedioic Acid Bis{[3,5-bis(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]amide} Octacosasodium Salt**

25

A solution of decanedioic acid bis{[3,5-bis(β -cellobiosyloxymethyl)phenyl]-amide (177 mg, 98.4 μ mol) and sulfur trioxide trimethylamine complex (1.97 g, 14.2 mmol) in DMF (25 mL) was stirred at 70°C for 25 h. The reaction mixture was concentrated and purified by chromatography with Sephadex G-10 using water elution. Cation exchange using a column of Dowex 50 x 8 strongly acidic resin (Na form) provided 292 mg (64% yield) after azeotropic drying with toluene: partial ¹H-NMR (D₂O; 400 MHz) δ 7.55 (s, 4 H), 7.35 (s, 2 H), 4.96 - 4.98 (m, 8 H), 2.45 (br t, 4 H), 1.40 - 1.60 (br t, 4 H), and 1.36 - 1.41 ppm (br m, 12 H); ¹³C-NMR (D₂O; 100 MHz) δ 176.1, 138.0, 137.1, 124.5, 121.0, 99.9, 99.6, 77.6, 77.43, 77.39, 77.0, 74.3,

30

35

- 28 -

73.4, 72.9, 70.9, 67.6, 66.3, 36.5, 28.7, 28.5, and 25.3 ppm. Anal. Calcd. for $C_{76}H_{92}N_2O_{30} \cdot 3 Na_2SO_4 \cdot 28 H_2O$: C, 16.34; H, 2.67; N, 0.50; S, 17.8. Found: C, 16.25; H, 2.63; H, 0.59; S, 17.07.

5

EXAMPLE 15**Step 1****Biphenyl-4,4'-dicarboxylic Acid Bis{[3,5-bis(β -D-cellobiosyloxymethyl)phenyl]amide}**

10

To a solution of 3,5-bis(hepta-O-acetyl- β -D-cellobiosyloxymethyl)-phenylamine (817 mg, 0.588 mmol) and triethylamine (86 μ L, 0.62 mmol) in THF (25 mL) was added 4,4-biphenyldicarboxylic acid dichloride (86 mg, 0.309 mmol). After stirring at room temperature for 2 h, the reaction mixture was quenched with MeOH, diluted with CH_2Cl_2 , and washed with H_2O . The reaction mixture was dried (MgSO₄) and concentrated to give 921 mg of crude product, which was dissolved in MeOH (20 mL) and treated with 9.3 mL of 1 N NaOH. After stirring at 50°C for 4 h, 8.6 mL (8.6 mmol) of 1 N HCl was added to the cooled reaction mixture. Collection of the solid provided 482 mg (86% yield) of the title compound: partial ¹H-NMR (DMSO-d₆; 400 MHz) δ 10.40 (s, 2 H), 8.11 (d, 4 H), 7.93 (d, 4 H), 7.74 (s, 4 H), 7.18 (s, 2 H), 4.86 (d, 4 H), 4.56 (d, 4 H), 4.35 (d, 4 H), 4.27 (d, 4 H), 3.80 (d, 4 H), and 2.97 - 3.07 ppm (m, 4 H); ¹³C-NMR (DMSO-d₆, 100 MHz) δ 165.0, 142.0, 138.9, 138.2, 134.1, 128.5, 126.9, 122.8, 119.3, 103.2, 102.0, 80.5, 76.8, 76.5, 75.1, 75.0, 73.3, 73.2, 70.02, 69.96, 61.0, and 60.4 ppm; IR (KBr) 1650 cm⁻¹. Anal. Calcd. for $C_{78}H_{108}N_2O_{46} \cdot 10 H_2O$: C, 47.08; H, 6.48; N, 1.41. Found: C, 46.64; H, 6.22; N, 1.62.

20

25

Step 2**Biphenyl-4,4'-dicarboxylic Acid Bis{[3,5-bis(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]amide} Octacosasodium Salt**

30

A solution of 338 mg (0.187 mmol) of biphenyl-4,4'-dicarboxylic acid bis{[3,5-bis(β -D-cellobiosyloxymethyl)phenyl]amide} and 3.64 g (26.1 mmol) of sulfur trioxide trimethylamine complex in DMF (25 mL) was stirred at 70°C for 2 days. The reaction mixture was cooled to ambient temperature, quenched with water,

35

- 29 -

and concentrated. Purification was achieved with a Sephadex G-10 column (H₂O elution). Cation exchange was accomplished by passing an aqueous solution of the product through a column of Dowex 50 x 8 strongly acidic (Na form) resin. Removal of solvent and azeotropic drying with toluene gave 765 mg (88% yield) of the title compound as an off-white solid, mp 180°C (dec): partial ¹H-NMR (D₂O; 400 MHz) δ 8.08 (d, 4 H), 7.97 (d, 4 H), 7.70 (s, 4 H), 7.39 (s, 2 H), 5.02 (d, 4 H), 4.98 (d, 4 H), 4.15 - 4.23 (m, 8H), and 4.00 ppm (m, 8 H); ¹³C-NMR (D₂O, 100 MHz) δ 169.2, 143.3, 138.2, 137.3, 133.5, 128.3, 127.5, 125.0, 121.8, 100.0, 99.7, 77.7, 77.54, 77.51, 77.1, 74.4, 73.5, 73.0, 71.0, 67.7, and 66.4 ppm; mass spectrum (electrospray) (*m/zNa*)/*z* 401.3 (*m* - 11Na)¹¹⁻, 443.7 (*m* - 10Na)¹⁰⁻, 495.6 (*m* - 9Na)⁹⁻, 560.4 (*m* - 8Na)⁸⁻, and 643.7 (*m* - 7Na)⁷⁻.
Anal. Calcd. for C₇₈H₈₀N₂O₁₃₀S₂₈Na₂₈•2 Na₂SO₄•28 H₂O:
C, 17.17, H, 2.51; N, 0.51; S, 16.46. Found: C, 17.06; H, 2.11; N, 0.55; S, 12.04.

15

EXAMPLE 16**Step 1****Biphenyl-4,4'-dicarboxylic Acid Bis{[3,5-Bis(hepta-O-acetyl-β-D-lactosyloxymethyl)phenyl]amide}**

20

To a solution of 3, 5-bis(hepta-O-acetyl-β-D-lactosyloxymethyl)phenylamine (1.05 g, 0.757 mmol) and triethylamine (105 μL, 0.757 mmol) in THF (20 mL) was added 4,4-biphenyldicarboxylic acid dichloride (106 mg, 0.378 mmol). After stirring at room temperature for 2 h, the reaction mixture was quenched with MeOH, diluted with CH₂Cl₂, and washed with H₂O. The reaction mixture was dried (MgSO₄), concentrated, and purified by trituration from CH₂Cl₂ / Et₂O to give 984 mg (87% yield) of the title compound as a colorless solid, mp 163 - 167°C: ¹H (CDCl₃; 400 MHz) δ 8.62 (s, 2 H), 8.05 (d, 4 H), 7.74 (d, 4 H), 7.66 (s, 4 H), 6.93 (s, 2 H), 5.33 (d, 2 H), 5.17 (t, 2 H), 5.07 - 5.12 (m, 2 H), 4.91 - 4.97 (m, 4 H), 4.79 (d, 2 H), 4.62 - 4.66 (m, 4 H), 4.57 (d, 2 H), 4.51 (d, 2 H), 4.03 - 4.15 (m, 6 H), 3.80 - 3.88 (m, 4 H), 3.62 (dq, 2 H), 2.13 (s, 12 H), 2.10 (s, 12 H), 2.03 (s, 24 H), 2.02 (12 H), and 1.95 ppm (s, 12 H); mass spectrum (electrospray, Ca²⁺ adduct) *m/z* 1513.2 (*m* + Ca)²⁺.
Anal. Calcd. for C₁₃₄H₁₆₄N₂O₇₄ · 1 H₂O : C, 53.56; H, 5.57; N, 0.93. Found: C, 53.25; H, 5.55; N, 1.06.

35

- 30 -

Step 2**Biphenyl-4,4'-dicarboxylic Acid Bis{[3,5-bis(hepta-O-sulfato- β -D-lactosyloxymethyl)phenyl]amide} Octacosasodium Salt**

5 A solution of 871 mg (0.292 mmol) of biphenyl-4,4'-dicarboxylic acid bis{[3,5-bis(hepta-O-acetyl- β -D-lactosyloxymethyl)phenyl]amide} in MeOH (15 mL) containing 8.75 mL of 1 N NaOH (8.75 mmol) was stirred at 50°C for 3 h. The reaction mixture was cooled to ambient temperature and was quenched with 8.16 mL (8.16 mmol) of 1 N HCl. The resulting solid was collected and azeotropically dried
10 with toluene: $^{13}\text{C-NMR}$ (DMSO- d_6 ; 100 MHz) δ 164.9, 141.9, 138.9, 138.2, 134.1, 128.4, 126.8, 119.2, 103.8, 101.9, 80.7, 75.5, 74.99, 74.96, 73.3, 73.2, 70.6, 69.9, 68.0, 60.5, and 60.3 ppm.

A solution of 396 mg (0.219 mmol) of biphenyl-4,4'-dicarboxylic acid
15 bis{[3,5-bis-(β -D-lactosyloxymethyl)phenyl]amide} and 4.26 g (30.6 mmol) of sulfur trioxide trimethylamine complex in DMF (20 mL) was stirred at 70°C for 3 days. The reaction mixture was cooled to ambient temperature, quenched with distilled H₂O, and concentrated. The residue was purified by passing through a Sephadex G-10 column (H₂O elution). Cation exchange was accomplished by passing an aqueous
20 solution of the product through a column of Dowex 50 x 8 strongly acidic (Na form) resin. Removal of solvent and azeotropic drying with toluene gave 664 mg (65%) of a shiny white solid, mp 149°C (dec): $^{13}\text{C-NMR}$ (D₂O; 100 MHz) δ 169.1, 143.1, 138.1, 137.3, 133.4, 128.2, 127.4, 124.9, 121.7, 100.9, 99.4, 77.6, 77.0, 75.8, 75.3, 75.05, 75.00, 73.0, 71.1, and 66.34 ppm; mass spectrum (electrospray) ($m-z\text{Na}$)/ z
25 643.7 ($m - 7 \text{ Na}$)⁷⁻, 754.8 ($m - 6 \text{ Na}$)⁶⁻ and 910.4 ($m - 5 \text{ Na}$)⁵⁻. Anal. Calcd. for C₇₈H₈₀N₂O₁₃₀S₂₈Na₂₈ · 28 H₂O: C, 18.12; H, 2.65; N, 0.54; S, 17.36. Found: C, 18.06; H, 2.67; N, 0.50; S, 14.75. (NMR and capillary electrophoresis show one major component and several minor components; mass spectrum analysis indicates products from 20 - 28 sulfates).

30

- 31 -

EXAMPLE 17**Step 1****Biphenyl-4,4'-dicarboxylic Acid Bis{[3,5-bis(tetra-O-acetyl-β-D-glucosyloxymethyl)phenyl]amide}**

5
10
15
20

To a solution of 3, 5-bis(tetra-O-acetyl-β-D-glucosyloxymethyl)phenylamine (996 mg, 1.22 mmol) and triethylamine (160 μL, 1.22 mmol) in THF (15 mL) was added 4,4'-biphenyldicarboxylic acid dichloride (171 mg, 0.612 mmol). After stirring at room temperature for 3 h, the reaction mixture was quenched with MeOH, diluted with CH₂Cl₂, and washed with H₂O. The reaction mixture was dried (MgSO₄), concentrated, and purified by trituration from CH₂Cl₂ / Et₂O to give 984 mg (87% yield) of the title compound as a colorless solid, mp 125 - 130 °C: ¹H (CDCl₃; 400 MHz) δ 8.42 (s, 12 H), 8.04 (d, 4 H), 7.75 (d, 4 H), 7.66 (s, 4 H), 6.98 (s, 2 H), 5.03 - 5.22 (m, 12 H), 4.85 (d, 4 H), 4.67 (d, 4 H), 4.61 (d, 4 H), 4.22 - 4.32 (m, 8 H), 3.72 (dq, 4 H), 2.06 (s, 12 H), 2.024 (s, 12 H), 2.019 s, 12 H), and 1.99 ppm (s, 12 H); mass spec ((-)-FAB), *m/z* 1159 (M-H). Anal. Calcd. for C₅₄H₆₈N₂O₂₆·6H₂O: C, 51.10; H, 6.35; N, 2.21. Found: C, 51.01; H, 6.09; N, 2.25.

Step 2**Biphenyl-4,4'-dicarboxylic Acid Bis{[3,5-bis(β-D-glucosyloxymethyl)phenyl]amide}**

25
30
35

A solution of 575 mg (0.495 mmol) of biphenyl-4,4 dicarboxylic acid bis{[3,5-bis-(tetra-O-acetyl-β-D-glucosyloxymethyl)phenyl]amide} and 8.91 mL (8.9 mmol) of 1 N NaOH in MeOH (15 mL) was stirred at 50°C for 4 h. The reaction mixture was quenched with 1 N HCl (7.9 mL) and purified by Sephadex G-10 chromatography (H₂O elution). Removal of H₂O *in vacuo* gave 144 mg (25% yield) of the title compound, mp 160°C (dec): ¹H (D₂O; 400 MHz) δ 7.38 (d, 4 H), 7.20 (s, 4 H), 7.16 (d, 4 H), 7.07 (s, 2 H), 4.72 (d, 4 H), 4.47 (d, 4 H), 4.38 (d, 4 H), 3.88 (d, 4 H), 3.69 (dd, 4 H), and 3.27 - 3.44 ppm (m, 16 H); ¹³C-NMR (D₂O; 100 MHz) δ 166.3, 141.6, 137.6, 137.2, 131.7, 127.5, 126.3, 124.0, 120.1, 101.5, 75.7, 75.6, 73.0, 70.7, 69.5, and 60.6 ppm; mass spectrum ((-)-FAB) *m/z* 1159.4 (M - H), 997.3, 981.3, and 699.2. Anal. Calcd. for C₅₄H₆₈N₂O₂₆·6H₂O: C, 51.10; H, 6.35; N, 2.21. Found: C, 51.01; H, 6.09; N, 2.25.

- 32 -

Step 3**Biphenyl-4,4'-dicarboxylic Acid Bis{[3,5-bis(tetra-O-sulfato-β-D-glucosyloxymethyl)phenyl]amide} Hexadecasodium Salt**

5 A solution of 92 mg (0.079 mmol) of biphenyl-4,4'-dicarboxylic acid bis{[3,5-bis(β-D-glucosyloxymethyl)phenyl]amide} and 450 mg (6.83 mmol) of sulfur trioxide trimethylamine complex in DMF (15 mL) was stirred at 70°C for 3 days. The reaction mixture was cooled to ambient temperature, quenched with distilled H₂O, and concentrated. The residue was purified by passing through a Sephadex G-10 column (H₂O elution). Cation exchange was accomplished by passing an aqueous solution of the product through a column of Dowex 50 x 8 strongly acidic (Na form) resin. Removal of solvent and azeotropic drying with toluene gave 161mg (73%) of a shiny white solid, mp 172°C (dec): ¹H-NMR (D₂O; 400 MHz) δ 8.10 (dd, 4 H), 7.97 (dd, 4 H), 7.71 (s, 4 H), 7.40 (s, 2 H), 5.05 (d, 4 H), 5.01 (dd, 4 H), 4.89 (d, 4 H), 4.47 - 4.60 (m, 12 H), 4.28 (dt, 4 H), and 4.19 - 4.22 ppm (m, 4 H); ¹³C-NMR (D₂O; 100 MHz) δ 169.1, 143.1, 138.0, 137.3, 133.4, 128.2, 127.3, 125.0, 121.8, 99.3, 76.0, 75.7, 73.4, 72.5, 70.8, and 67.7 ppm. Anal. Calcd. for C₅₄H₅₂N₂O₇₄S₁₆N₁₆·16H₂O: C, 21.01; H, 2.75; N, 0.91; S, 16.65. Found: C, 20.93; H, 2.78; N, 0.77; S, 16.86. Capillary electrophoresis shows purity in excess of 91%.

20

EXAMPLE 18**Step 1****Biphenyl-4,4'-dicarboxylic Acid Bis{[3,5-bis(hepta-O-acetyl-β-D-maltosyloxymethyl)phenyl]amide}**

25

To a solution of 3,5-bis(hepta-O-acetyl-β-D-maltosyloxymethyl)phenylamine (1.07 g, 0.769 mmol) and triethylamine (101 μL, 0.769 mmol) in THF (20 mL) was added 4,4'-biphenyldicarboxylic acid dichloride (107 mg, 0.385 mmol). After stirring at room temperature for 3 h, the reaction mixture was quenched with MeOH, diluted with CH₂Cl₂, and washed with H₂O. The reaction mixture was dried (MgSO₄) and concentrated to give 1.10 g (96% yield) of the title compound as a colorless solid, mp 139 - 144°C: ¹H-NMR (CDCl₃, 400 MHz) δ 8.66 (bs, 2 H), 8.03 (d, 4 H), 7.72 (d, 4 H), 7.67 (s, 4 H), 6.93 (s, 2 H), 5.39 (d, 4 H), 5.32 (t, 4 H), 5.20 (t, 4 H), 5.02 (t, 4 H), 4.76 - 4.86 (m, 12 H), 4.57 - 4.66 (m, 12 H), 4.20 - 4.25 (m, 8 H), 3.93 - 4.04 (m, 12 H), 3.6 - 3.7 (m, 4 H), 2.09 (s, 12 H), 2.06 (s, 12 H), 1.99 (s, 12 H), 1.98 (s, 12 H),

30
35

- 33 -

1.97 (s, 12 H), 1.96 (s, 12 H), and 1.95 ppm (s, 12 H); IR (KBr)1745 cm^{-1} . Anal. Calcd. for $\text{C}_{134}\text{H}_{164}\text{N}_2\text{O}_{74}$: C, 53.89; H, 5.53; N, 0.94. Found: C, 53.49; H, 5.55; N, 0.94.

5

Step 2**Biphenyl-4,4'-dicarboxylic Acid Bis{[3, 5-bis(β -D-maltosyloxymethyl)phenyl]amide}**

A solution of 973 mg (0.326 mmol) of biphenyl-4,4'-dicarboxylic acid bis{[3,5-bis(hepta-O-acetyl- β -D-maltosyloxymethyl)phenyl]amide} and 9.77 mL (9.77 mmol) of 1 N NaOH in MeOH (15 mL) was stirred at 50°C for 4 h. The reaction mixture was cooled to room temperature, quenched with 1 N HCl (9.12 mL), concentrated, and purified by Sephadex G-10 chromatography (H_2O elution). Removal of H_2O *in vacuo* gave 494 mg (75% yield) of the title compound, mp >200°C: $^1\text{H-NMR}$ (D_2O , 400 MHz) δ 7.54 (s, 4 H), 7.33 (s, 4 H), 7.23 - 7.27 (br, 4 H), 7.15 (s, 2 H), 5.32 (s, 4 H), 4.51 - 4.20 (brd 4 H), 4.39 (d, 4 H), 3.50 - 3.90 (m, 36 H), and 3.30 - 3.45 ppm (m, 12 H); $^{13}\text{C-NMR}$ (D_2O ; 100 MHz) δ 166.3, 141/7, 137.8, 137.3, 132.0, 127.7, 126.5, 124.1, 120.1, 101.3, 99.9, 77.4, 75.9, 74.4, 72.8, 72.6, 71.6, 70.6, 69.1, 60.6, and 60.3 ppm. Anal. Calcd. for $\text{C}_{78}\text{H}_{108}\text{N}_2\text{O}_{46}\cdot 8\text{H}_2\text{O}$:
20 C, 48.85; H, 6.31; N, 1.46. Found: C, 48.48; H, 6.28; N, 1.58.

Step 3**Biphenyl-4,4'-dicarboxylic Acid Bis{[3, 5-bis(hepta-O-sulfato β -D-maltosyloxymethyl)phenyl]amide} Octacosasodium Salt**

25

A solution of 315 mg (0.174 mmol) of biphenyl-4,4'-dicarboxylic acid bis{[3,5-bis(β -D-maltosyloxymethyl)phenyl]amide} and 3.58 g, (25.7 mmol) of sulfur trioxide trimethylamine complex in DMF (15 mL) was stirred at 70°C for 3 days. The reaction mixture was cooled to ambient temperature, quenched with distilled H_2O , and concentrated. The residue was purified by passing through a Sephadex G-10 column (H_2O elution). Cation exchange was accomplished by passing an aqueous solution of the product through a column of Dowex 50 x 8 strongly acidic (Na form) resin. Removal of solvent and azeotropic drying with toluene gave 609mg (75%) of an off-white solid, mp 178°C (dec): $^1\text{H-NMR}$ (D_2O ;
30 400 MHz) δ 8.06 (d, 4 H), 7.94 (d, 4 H), 7.69 (s, 4 H), 7.36 (s, 2 H), 5.58 (d, 4 H),
35

- 34 -

5.06 (d, 4 H), 5.02 (d, 4 H), 4.7 - 4.9 (m, 12 H), 4.58 - 4.61 (m, 8 H), 4.49 (dd, 4 H), 4.12 - 4.46 ppm (m, 28 H); $^{13}\text{C-NMR}$ (D_2O ; 100 MHz) δ 169.1, 143.1, 138.0, 137.3, 133.4, 128.2, 127.4, 124.9, 121.7, 99.3, 94.1, 77.1, 76.0, 74.8, 73.2, 73.1, 72.3, 71.8, 70.5, 69.9, 67.5, and 66.0 ppm; mass spectrum (electrospray) ($m-z/\text{Na}$)/ z 1143.7 ($m-4 \text{ Na}$) $^{4-}$, 910.4 ($m-5 \text{ Na}$) $^{5-}$, 754.8 ($m-6 \text{ Na}$) $^{6-}$, 643.7 ($m-7 \text{ Na}$) $^{7-}$, 560.4 ($m-8 \text{ Na}$) $^{8-}$.
Calcd. for $\text{C}_{78}\text{H}_{80}\text{N}_2\text{O}_{130}\text{S}_{28}\text{Na}_{28}\cdot 28\text{H}_2\text{O}$: C, 18.12; H, 2.65; N, 0.54; S, 17.36.
Found: C, 18.33; H, 2.73; N, 0.46; S, 17.72.

EXAMPLE 19

10

Step 1

3,3'-(N,N'-Ureido)bis[N-[5-(hepta-O-acetyl- β -D-cellobiosyloxymethyl)-2-chlorophenyl]benzamide]

15 To a solution of 1.10 g (1.42 mmol) of 5-(hepta-O-acetyl- β -D-cellobiosyloxymethyl)-2-chlorophenylamine in THF (20 mL) containing 198 μL (1.42 mmol) of triethylamine was added 3-nitrobenzoyl chloride (316 mg, 1.70 mmol). After 3 h, the reaction mixture was quenched with MeOH and diluted with CH_2Cl_2 . The reaction mixture was washed with H_2O , dried (MgSO_4), filtered, and
20 concentrated to 1.31 g (1.42 mmol) of crude product which was used directly in the next reaction. The crude material was dissolved in EtOAc and was treated with 2.32 g (10.28 mmol) of $\text{SnCl}_2\cdot\text{H}_2\text{O}$. After stirring at reflux for 5 h, the reaction mixture was cooled to room temperature and was quenched with sat. NaHCO_3 (300 mL). The reaction mixture was diluted with EtOAc, and filtered. The organic phase was
25 separated and the aqueous phase was extracted with CH_2Cl_2 . The organic phases were combined, dried (MgSO_4) and concentrated to give 1.18 g (93% yield) of crude product which was used directly in the next reaction. To the product in THF (20 mL) containing 108 μL (7.98 mmol) of pyridine was added 66 mg (0.22 mmol) of triphosgene. The mixture was stirred at ambient temperature overnight. The reaction
30 mixture was quenched with H_2O and then stirred for another 30 min. The reaction mixture was filtered. The solid was collected and dissolved in CH_2Cl_2 , dried (MgSO_4), concentrated, and then triturated with Et_2O to give 995 mg (82% yield) of the title compound, mp 173 - 178°C: $^1\text{H-NMR}$ (CDCl_3 , 400 MHz) δ 8.47 (s, 2 H), 8.41 (d, 2 H), 7.45 (d, 2 H), 7.38 (t, 2 H), 7.33 (d, 2 H), 6.96 (dd, 2 H), 5.10 - 5.16 (m, 4 H), 5.03 (t, 2 H), 4.90 - 4.96 (m, 4 H), 4.79 (d, 2 H), 4.59 (t, 2 H), 4.51 - 4.56 (m, 4 H), 4.30 (dd, 1 H), 4.14 (dd, 1 H), 3.99 (dd, 2 H), 3.92 (t, 2 H), 3.65 - 3.70 (dq, 2H),

- 35 -

2.09 (s, 6 H), 2.04 (s, 6 H), 2.02 (s, 12 H), 1.987 (s, 6 H), 1.985 (s, 6 H), and 1.96 ppm (s, 6 H); ^{13}C -NMR (CDCl_3 ; 100 MHz) δ 170.6, 170.49, 170.46, 169.83, 169.17, 169.14, 165.22, 152.47, 139.75, 136.78, 134.85, 134.43, 129.68, 129.13, 124.35, 123.08, 122.95, 121.18, 120.57, 117.99, 100.70, 98.92, 73.22, 72.64, 71.89, 71.74, 5 71.55, 71.49, 69.97, 67.90, 62.04, 61.53, 20.86, 20.72, 20.64, 20.58, 20.53, and 20.45 ppm; mass spectrum ((+)-FAB) m/z 1837.5 (M + Na). Anal. Calcd. for $\text{C}_{81}\text{H}_{92}\text{N}_4\text{O}_{39}\text{Cl}_2\cdot\text{H}_2\text{O}$: C, 53.03; H, 5.16; N, 3.05. Found: C, 52.74; H, 5.09; N, 3.15.

10

Step 2**3,3'-(N,N'-Ureido)bis{N-[5-(β -D-cellobiosyloxymethyl)-2-chlorophenyl]benzamide}**

A solution of 908 mg (0.50 mmol) of 3,3'-(N,N'-ureido)bis{N-[5-(hepta-O-acetyl- β -cellobiosyloxymethyl)-2-chlorophenyl]benzamide} in MeOH (20 mL) 15 containing 7.5 mL (7.5 mmol) of 1 N NaOH was stirred at 50°C under N_2 for 4 h. The reaction mixture was cooled to room temperature and was quenched with 1 N HCl (7.0 mL, 7.0 mmol). The reaction mixture was stirred for 15 min and filtered. The solid was collected and azeotropically dried with toluene to provide 566 mg 20 (92% yield) of the title compound as an off-white solid, mp 183°C: partial ^1H -NMR (DMSO- d_6 , 400 MHz) δ 10.06 (s, 2 H), 9.28 (s, 2 H), (s, 1 H), 2 H), 7.75 (d, 1 H), 7.60 (d, 2 H), 7.59 (s, 2 H), 7.50 - 7.55 (q, 4 H), 7.44 (d, 2 H), 7.33 (dd, 2 H), 5.30 (s, 2 H), 5.25 (d, 2 H), 4.86 (d, 2 H), 4.70 (s, 2 H), 4.33 (d, 2 H), 4.25 (d, 2 H), 3.75 - 3.80 (dd, 2 H), 3.60 - 3.71 (m, 4 H), and 3.0 - 3.2 ppm (m, 8 H); ^{13}C -NMR (DMSO- 25 d_6 ; 100 MHz) δ 165.54, 152.70, 140.05, 137.74, 134.90, 134.78, 129.27, 128.95, 128.48, 127.36, 126.53, 121.58, 120.91, 117.80, 103.21, 101.99, 80.49, 76.79, 76.46, 75.01, 73.29, 73.19, 70.04, 68.82, 61.02, and 60.43 ppm; mass spectrum ((+)-FAB) m/z 1249.2 (M + Na). Anal. Calcd. for $\text{C}_{53}\text{H}_{64}\text{N}_4\text{O}_{25}\text{Cl}_2\cdot 4\text{H}_2\text{O}$: C, 48.97; H, 5.58; N, 4.31. Found: C, 49.25; H, 5.58; N, 4.28.

30

- 36 -

Step 3**3,3'-(N,N'-Ureido)bis{(N-[2-chloro-5-(hepta-O-sulfato-β-D-cellobiosyloxymethyl)phenyl]}benzamide) Tetradecasodium Salt**

5 To a solution of 3,3'-(N,N'-ureido)bis{N-[5-(β-cellobiosyloxymethyl)-2-chlorophenyl]benzamide} (475 mg, 0.387 mmol) in DMF (25 mL) containing 3.77 g (27.08 mmol) of sulfur trioxide trimethylamine complex was stirred at 70°C for 3 days. The reaction mixture was cooled to room temperature, quenched with distilled H₂O, and concentrated. The residue was purified by passing through a Sephadex G-10 column (H₂O elution). Cation exchange was accomplished by passing an aqueous solution of the product through a column of Dowex 50 x 8 strongly acidic (Na form) resin. Removal of solvent and azeotropic drying with toluene gave 926 mg (0.349 mmol) of the title compound as an off-white solid, mp 168°C (dec): ¹³C-NMR (D₂O; 100 MHz) δ 169.46, 155.29, 138.29, 136.85, 133.89, 133.06, 129.90, 129.63, 129.56, 15 128.43, 127.62, 124.74, 122.79, 119.59, 99.91, 99.14, 77.61, 77.32, 77.03, 74.28, 73.63, 73.34, 70.0, 67.60, and 66.60 ppm. Anal. Calcd. for C₅₃H₅₀N₄O₆₇S₁₄Na₁₄·3Na₂SO₄·18H₂O: C, 19.08; H, 2.60; N, 1.68; S, 16.34. Found: C, 19.01; H, 2.21; N, 1.74; S, 16.82. Capillary zone electrophoresis shows >90% purity.

20

EXAMPLE 20**Step 1****Biphenyl-4,4'-dicarboxylic Acid Bis{[2-chloro-5-(β-D-cellobiosyloxymethyl)phenyl]amide}**

25

To a solution of 5-(hepta-O-acetyl-β-D-cellobiosyloxymethyl)-2-chlorophenylamine (995 mg, 1.28 mmol) and triethylamine (148 μL, 1.28 mmol) in THF (25 mL) was added 4,4'-biphenyldicarboxylic acid dichloride (179 mg, 0.642 mmol). After stirring at room temperature for 2 h, the reaction mixture was quenched with MeOH, diluted with CH₂Cl₂, and washed with H₂O. The reaction mixture was dried (MgSO₄) and concentrated to an oil which was triturated with ether to provide 1.09 g of crude product (99% yield). The material was dissolved in MeOH (20 mL) and treated with 9.5 mL of 1 N NaOH. After stirring at 50°C for 4 h, the reaction mixture was cooled to room temperature and treated with 8.9 mL (8.9 mmol) of 1 N HCl. Collection of the solid provided 670 mg (91% yield) of the title compound, mp 30 35

- 37 -

>200°C, after azeotropic drying with toluene: partial ¹H-NMR (DMSO-d₆; 400 MHz) δ 10.21 (s, 2 H), 8.13 (d, 4 H), 7.95 (d, 4 H), 7.61 (d, 2 H), 7.55 (d, 2 H), 7.35 (dd, 2 H), 5.27 (d, 2 H), 5.25 - 5.26 (br, 2 H), 4.87 (d, 2 H), 4.71 (s, 2 H), 4.34 (d, 2 H), 4.26 (d, 2 H), 3.78 (dd, 2 H), 3.15 (br d, 2 H), and 3.05 ppm (br t, 2 H); partial ¹³C-NMR (DMSO-d₆; 100 MHz) δ 165.0, 128.5, 127.0, 103.2, 102.0, 80.5, 76.8, 76.4, 75.0, 73.3, 73.2, 70.0, 68.8, 61.0, and 60.4 ppm.; mass spectrum (-FAB) *m/z* 1166.9, 1004.9, and 842.9. Anal. Calcd. for C₅₂H₆₂N₂O₂₄Cl₂•5 H₂O: C, 49.57; H, 5.76; N, 2.22. Found: C, 49.81; H, 5.36; N, 2.14.

10

Step 2**Biphenyl-4,4'-dicarboxylic Acid Bis{[2-chloro-5-(hepta-O-sulfato-β-D-cellobiosyloxymethyl)phenyl]amide} Tetradecasodium Salt**

A solution of 531 mg (0.454 mmol) of biphenyl-4,4'-dicarboxylic acid bis{[2-chloro-5-(β-D-cellobiosyloxymethyl)phenyl]amide} and 4.42 g (31.8 mmol) of sulfur trioxide trimethylamine complex in DMF (25 mL) was stirred at 70°C for 2 days. The reaction mixture was concentrated and purified by Sephadex G-10 chromatography using H₂O elution. Cation exchange was effected using a column of Dowex 50 x 8 strongly acidic (Na form) with H₂O elution. Removal of water *in vacuo* and azeotropic drying with toluene gave 705 mg (60%) of the title compound as a white solid, mp 165°C (dec): partial ¹H-NMR (DMSO-d₆; 400 MHz) δ 8.10 (d, 4 H), 7.97 (d, 4 H), 7.66 (d, 2 H), 7.65 (d, 2 H), 7.52 (dd, 2 H), 4.99 (d, 2 H), 4.97 (d, 2 H), 4.58 (d, 2 H), and 4.00 - 4.06 ppm (m, 4 H); ¹³C-NMR (D₂O; 100 MHz) δ 169.8, 143.5, 137.0, 133.2, 132.6, 130.04, 130.01, 128.7, 128.3, 128.0, 127.5, 99.9, 99.2, 77.7, 77.4, 77.1, 74.3, 73.6, 73.4, 73.2, 67.7, and 66.6 ppm; mass spectrum (electrospray) (*m-zNa*)/*z* 496.7 (*m - 5Na*)⁵⁻, 626.6 (*m-4Na*)⁴⁻, and 843.2 (*m-3Na*)³⁻. Anal. Calcd. for C₅₂H₄₈Cl₂N₂Na₁₄O₆₆S₁₄•16 H₂O: C, 21.63; H, 2.79; N, 0.97; S, 15.55. Found: C, 21.24; H, 2.31; N, 0.93; S, 12.25.

- 38 -

EXAMPLE 21**Step 1****Biphenyl-4,4'-dicarboxylic Acid Bis{[2-(β -D-cellobiosyloxymethyl)-4-chlorophenyl]amide}**

5
10
15
20
25

To a solution of 861 mg (1.11 mmol) of 2-(hepta-O-acetyl- β -D-cellobiosyloxymethyl)-4-chlorophenylamine and triethylamine (155 μ L, 1.11 mmol) in THF (20 mL) was added 4,4'-biphenyldicarboxylic acid dichloride (155 mg, 0.555 mmol). After stirring at ambient temperature for 2 h, the reaction mixture was quenched with MeOH, diluted with CH₂Cl₂ and washed with H₂O. The organic phase was dried (MgSO₄), filtered, and concentrated to give 975 mg of crude product. This material was dissolved in MeOH (15 mL) and was treated with 8.3 mL (8.3 mmol) of 1 N NaOH. After stirring for 4 h at ambient temperature, the reaction mixture was quenched with 7.8 mL of 1 N HCl and the solid was collected to provide 590 mg (91% yield) of the title compound as an off-white solid, mp >200°C: partial ¹H-NMR (DMSO-d₆; 400 MHz) δ 9.95 (s, 2 H), 8.11 (d, 4 H), 7.93 (d, 4 H), 7.67 (d, 2 H), 7.62 (d, 2 H), 7.42 (dd, 2 H), 5.45 (d, 2 H), 4.91 (d, 2 H), 4.34 (d, 2 H), and 4.25 ppm (d, 2 H); partial ¹³C-NMR (DMSO-d₆; 100 MHz) δ 164.9, 142.2, 134.6, 134.5, 133.4, 128.5, 127.0, 103.2, 101.7, 80.4, 80.2, 76.8, 76.4, 75.0, 74.9, 73.3, 70.0, 66.3, 61.0, and 60.3 ppm; IR (KBr) 1650 cm⁻¹; mass spectrum (-FAB) *m/z*: 1167.3, 843.3, and 704.2. Anal. Calcd. for C₅₂H₆₂Cl₂N₂O₂₄·4 H₂O: C, 50.29; H, 5.68; N, 2.26. Found: C, 50.37; H, 5.38; N, 2.32.

Step 2**Biphenyl-4,4'-dicarboxylic Acid Bis{[4-chloro-2-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]amide} Tetradecasodium Salt**

30
35

A solution of 447 mg (0.382 mmol) of biphenyl-4,4'-dicarboxylic acid bis{[2-(β -D-cellobiosyloxymethyl)-4-chlorophenyl]amide} and 3.85 g (27.7 mmol) of sulfur trioxide trimethylamine complex in DMF (25 mL) was stirred at 70°C for 6 days. The reaction mixture was quenched at room temperature with H₂O, concentrated, and passed through a Sephadex G-10 column (H₂O elution). Cation exchange was effected by passing an aqueous solution of the compound through a Dowex 50 x 8 strongly acidic (Na form) cation exchange column (H₂O elution). Removal of solvent and azeotropic drying with toluene gave 666 mg (67% yield) of the title

- 39 -

compound as an off-white solid, mp 172°C, which was ca. 70% pure as determined by capillary electrophoresis: partial ¹H-NMR (D₂O; 400 MHz) δ 8.10 (d, 4 H), 7.99 (d, 4 H), 7.74 (s, 2 H), 7.46 - 7.53 (br, 4 H), 4.95 (d, 2 H), and 4.90 ppm (d, 2 H); ¹³C-NMR (D₂O; 100 MHz) δ 169.9, 143.4, 134.5, 133.4, 132.4, 129.7, 129.0, 128.7, 128.3, 127.6, 99.9, 98.8, 77.6, 77.4, 77.0, 74.3, 73.5, 73.4, 73.0, 67.6, 66.9, and 66.3 ppm. Anal. Calcd. for C₅₂H₄₈Cl₂N₂Na₁₄O₆₆S₁₄•14 H₂O: C, 21.92; H, 2.69; N, 98; S, 15.75. Found: C, 21.98; H, 2.63; N, 1.08; S, 16.05.

EXAMPLE 22

10

Step 1

N,N'-Bis[3,5-bis(β-D-cellobiosyloxymethyl)phenyl]succinamide

To a solution of 840 mg (0.604 mmol) 3, 5-bis(hepta-O-acetyl-β-D-cellobiosyloxymethyl)phenylamine and 86.4 μL (0.31 mmol) of triethylamine in THF (20 mL) was added succinyl chloride (34.2 μL, 0.31 mmol). After stirring at room temperature for 1 h, incomplete reaction was observed. Another 10 μL (0.09 mmol) of succinyl chloride was added. The reaction was stirred for another 15 min, quenched with MeOH, diluted with CH₂Cl₂, washed with H₂O, dried (MgSO₄), filtered, and concentrated. Trituration with Et₂O gave a green solid which was semi-purified by flash chromatography (EtOAc) to give a yellow solid (633 mg, 75% yield). The compound was dissolved in MeOH and was treated with 6.6 mL of 1 N NaOH (6.6 mmol). After stirring at 50°C for 4 h, the reaction mixture was cooled to room temperature and to it was added strongly acidic Amberlite resin until neutral pH was obtained. After stirring for 5 min, the reaction mixture was filtered and concentrated to a yellow solid. Purification by reverse phase chromatography (RP-60 silica gel) using elution of MeOH : H₂O (3 : 7) and then by Sephadex G-10 chromatography (H₂O elution) gave 278 mg (94%) of the title compound as a yellow solid: partial ¹H-NMR (D₂O; 400 MHz) δ 7.48 (s, 4 H), 7.31 (s, 2 H), 4.91 (d, 4 H), 4.71 (d, 4 H), 4.52 (t, 8 H), 3.82 (dd, 4 H), 3.74 (dd, 4 H), 3.43 (d, 4 H), and 2.81 ppm (s, 4 H); ¹³C-NMR (D₂O; 100 MHz) δ 173.3, 137.9, 137.3, 124.9, 120.9, 102.4, 101.0, 78.5, 75.8, 75.3, 74.6, 74.1, 73.0, 72.7, 70.7, 69.3, 60.4, 59.9, and 31.4 ppm.

- 40 -

Step 2**N,N'-Bis[3,5-bis(hepta-O-sulfato-β-D-cellobiosyloxymethyl)phenyl]succinamide
Octacosasodium Salt**

5 A solution of 278 mg (0.208 mmol) of N,N'-bis[3,5-bis(β-D-cellobiosyl-
oxymethyl)phenyl]succinamide and sulfur trioxide trimethylamine complex (4.23 g,
29.0 mmol) in DMF (20 mL) was stirred at 70°C for 3 days. The reaction mixture
was quenched at room temperature with H₂O and then concentrated. Purification by
Sephadex G-10 chromatography (H₂O elution) and then cation exchange using
10 Dowex 50 x 8 strongly acidic (Na form) resin gave 606 mg (64% yield) of the title
compound as a tan solid, mp 168°C (dec): partial ¹H-NMR (D₂O; 400 MHz) δ 7.58
(s, 4 H), 7.36 (s, 2 H), 4.00 - 5.00 (m, 64 H), and 2.87 ppm (s, 4 H); ¹³C-NMR (D₂O;
100 MHz) δ 173.3, 138.0, 137.1, 124.4, 99.9, 99.7, 77.6, 77.4, 77.0, 74.3, 73.4, 72.9,
70.9, 67.6, 66.2, and 37.1 ppm; mass spectrum (electrospray) (*m-zNa*)/*z* 734.1 (*m* -
15 6Na)⁶⁻, 885.5 (*m*-5Na)⁵⁻, and 1112.7 (*m*-4Na)⁴⁻. Anal. Calcd. for
C₆₈H₇₆N₂O₁₃₀S₂₈Na₂₈•38 H₂O: C, 15.62; H, 2.93; N, 0.54; S, 17.18. Found: C,
15.24; H, 2.43; N, 0.75; S, 17.67.

EXAMPLE 23**Step 1****N,N'-Bis[3,5-bis(β-D-cellobiosyloxymethyl)phenyl]terephthalamide**

20 To a solution of 3, 5-bis(hepta-O-acetyl-β-D-cellobiosyloxymethyl)-
phenylamine (823 mg, 0.592 mmol) and triethylamine (82.5 μL, 0.592 mmol) in THF
25 (15 mL) was added terephthaloyl chloride (60.1 mg, 0.296 mmol). After stirring at
ambient temperature for 2 h, the reaction mixture was quenched with MeOH, diluted
with CH₂Cl₂ and washed with H₂O. The organic phase was dried (MgSO₄), filtered,
concentrated, and triturated with Et₂O to provide 845 mg (98%) of crude product.
This was dissolved in MeOH (20 mL) and treated with 8.7 mL (8.7 mmol) of 1 N
30 NaOH. After stirring at 50°C for 3 h, the reaction mixture was cooled to ambient
temperature and 8.1 mL (8.1 mmol) of 1 N HCl was added. The solid was collected
and dried *in vacuo* to provide 295 mg (59% yield) of the title compound as a white
solid, mp 185°C (dec): partial ¹H-NMR (DMSO-d₆ with 5 drops D₂O; 400 MHz) δ
8.01 (s, 4 H), 7.64 (s, 4 H), 7.18 (s, 2 H), 4.81 (d, 2 H), 4.56 (d, 2 H), 4.33 (d, 2 H),
35 4.26 (d, 2 H), and 3.77 ppm (d, 2 H); ¹³C-NMR (DMSO-d₆; 100 MHz) δ 164.7,
138.7, 138.2, 137.3, 127.7, 122.9, 119.3, 103.2, 101.9, 80.5, 76.8, 76.4, 75.1, 75.0,

- 41 -

73.3, 73.2, 70.0, 69.9, 61.0, and 60.4 ppm; IR (KBr) 1650 cm^{-1} . Anal. Calcd. for $\text{C}_{72}\text{H}_{104}\text{N}_6\text{O}_{46} \cdot 12 \text{H}_2\text{O}$: C, 44.35; H, 6.62; N, 1.44. Found: C, 44.05; N, 6.30; N, 1.41.

5

Step 2**N,N'-Bis[3,5-bis(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]terephthalamide Octacosasodium Salt**

10 A solution of 178 mg (0.103 mmol) of N,N'-bis[3,5-bis(β -D-cellobiosyloxymethyl)phenyl]terephthalamide and sulfur trioxide trimethylamine complex (2.0 g, 14.4 mmol) in DMF (20 mL) was stirred at 70°C for 3 days. The reaction mixture was cooled, quenched with water, and concentrated. The residue was purified by Sephadex G-10 chromatography (H_2O elution). Cation exchange was
15 effected using a column of Dowex 50 x 8 strongly acidic (Na form) resin to afford 402 mg (85% yield) of the title compound as an off-white solid, mp 163°C (dec): partial $^1\text{H-NMR}$ (D_2O ; 400 MHz) δ 8.09 (s, 4 H), 7.71 (s, 4 H), 7.43 (s, 2 H), 5.03 (d, 2 H), and 5.00 ppm (d, 2 H); $^{13}\text{C-NMR}$ (DMSO-d_6 ; 100 MHz) δ 168.7, 138.1, 137.2, 137.1, 127.8, 125.0, 121.7, 99.9, 99.7, 77.6, 77.4, 77.0, 74.3, 73.4, 72.9, 70.9, 67.6,
20 and 66.3 ppm; mass spectrum (electrospray) ($m-z\text{Na}$)/ z : 632.8 ($m-7\text{Na}$) $^{7-}$, 742.1 ($m-6\text{Na}$) $^{6-}$, and 895.2 ($m-5\text{Na}$) $^{5-}$, and 1124.7 ($m-4$) $^{4-}$. Anal. Calcd. for $\text{C}_{72}\text{H}_{76}\text{N}_2\text{Na}_{28}\text{O}_{130}\text{S}_{28} \cdot 28 \text{H}_2\text{O}$: C, 16.97; H, 2.61; N, 0.55; S, 17.62. Found: C, 16.77; N, 2.41; N, 0.59; S, 17.42.

25

EXAMPLE 24**Step 1****Biphenyl-4,4'-disulfonic Acid Bis{[5-(β -D-cellobiosyloxymethyl)-2-methylphenyl]amide}**

30

To 970 mg (1.28 mmol) of 5-(hepta-O-acetyl- β -D-cellobiosyloxymethyl)-2-methylphenylamine in CH_2Cl_2 (20 mL) containing 1.0 mL (12.4 mmol) of pyridine was added 225 mg (0.641 mmol) of biphenyl-4,4'-disulfonyl chloride. After stirring at room temperature for 90 min, the reaction mixture was quenched with sat.
35 NaHCO_3 and extracted into EtOAc. The bright yellow organic phase was washed

- 42 -

with pH 7 buffer, dried (MgSO₄), and flash chromatographed (EtOAc / Et₂O / CH₂Cl₂, 1 : 1 : 1) to give 504 mg (58% yield) of an orange powder. This material (a total of 675 mg (0.378 mmol) from two separate runs) was dissolved in MeOH (10 mL) and THF (10 mL) and was treated with 6 mL of 1 N NaOH. After stirring at room temperature for 12 h, the reaction mixture was quenched with 6 mL of 1 N HCl, and was concentrated to ca. 6 - 8 mL. The resulting precipitate was collected and was washed with 15 mL of H₂O and then Et₂O. Azeotropic drying with toluene gave 335 mg (74% yield) of a pale yellow powder, mp 230°C (dec): ¹H-NMR (DMSO, 400 MHz) δ 9.69 (s, 2 H), 7.91 (d, 4 H), 7.75 (d, 4 H), 7.16 (d, 2 H), 7.11 (s, 2 H), 7.10 (d, 2 H), 4.71 (d, 2 H), 4.46 (d, 2 H), 4.24 - 4.28, 3.77 (d, 2 H), 3.70 (d, 2 H), 3.58 - 3.64 (m, 2 H), 2.97 - 3.43 (m, 18 H), and 1.91 ppm (s, 6 H); ¹³C-NMR (DMSO, 100 MHz) δ 142.2, 140.5, 136.1, 134.4, 132.9, 130.5, 127.8, 127.2, 126.0, 103.2, 101.6, 80.5, 76.7, 76.4, 75.1, 74.9, 73.2, 73.1, 70.0, 69.1, 61.0, 60.4, and 17.2 ppm; mass spectrum ((-)-FAB), *m/z* 1199.3, 750.2, 514.2. Anal. Calcd. for C₅₂H₆₈N₂O₂₆S₂·H₂O: C, 51.23; H, 5.79; N, 2.30. Found: C, 51.04; H, 5.64; N, 2.29.

Step 2

Biphenyl-4,4'-disulfonic Acid Bis[*(*2-methyl-5-(hepta-O-sulfato-β-D-cellobiosyloxymethyl)phenyl)amide] Tetradecasodium Salt

To 214 mg (0.178 mmol) of biphenyl-4,4'-disulfonic acid bis[*(*5-(β-D-cellobiosyloxymethyl)-2-methylphenyl)amide] in DMF (10 mL) was added 1.8 g (12.9 mmol) of sulfur trioxide trimethylamine complex. After stirring for 3 days at 70°C, the reaction mixture was cooled to room temperature, quenched with 10 mL of water, and stirred for 20 min. This was concentrated in vacuo and purified by gel filtration (Sephadex G-10) to give 419 mg of pale tan flakes. The compound was dissolved in a minimal amount of water and passed through an ion exchange column (Dowex 50 x 8 strongly acidic (Na-form)) to give 350 mg of pale tan flakes after azeotropic drying with toluene: ¹H-NMR (D₂O, 400 MHz) δ 7.89 (d, 4 H), 7.81 (d, 4 H), 7.39 (d, 2 H), 7.32 (s, 2 H), 7.25 (d, 2 H), 4.94 (d, 2 H), 4.65 - 4.87 (m, 8 H), 4.57 (dd, 2 H), 4.18 - 4.51 (m, 16 H), 3.98 - 4.05 (m, 4 H), and 1.90 ppm (s, 6 H); ¹³C-NMR (D₂O, 100 MHz) δ 143.8, 138.0, 135.4, 134.9, 131.1, 128.1, 128.0, 127.8, 127.3, 99.9, 98.7, 77.6, 77.3, 77.2, 76.9, 74.3, 73.7, 73.3, 72.93, 70.3, 67.6, 66.6., and 16.4 ppm. Anal. Calcd. for C₅₂H₅₄N₂Na₁₄O₆₈S₁₆·18 H₂O: C, 21.14; H, 3.05; N, 0.95. Found: C, 21.17; H, 2.71; N, 0.96.

EXAMPLE 25**Step 1****5 N,N'-Bis[2-methyl-5-(β-D-glucopyranosyloxymethyl)phenyl]succinamide**

To a solution of 879 mg (1.88 mmol) of 5-(tetra-O-acetyl-β-D-glucopyranosyloxymethyl)-2-methylphenylamine and 262 μL (1.88 mmol) of triethylamine in THF (10 mL) was added succinyl chloride (104 μL, 0.94 mmol).
10 After stirring at room temperature for 3 h, the reaction mixture was quenched with MeOH (20 mL), diluted with CH₂Cl₂, washed with H₂O, dried (MgSO₄), and concentrated. Crystallization from Et₂O gave 741 mg (78%) of a green solid which was used directly in the next reaction. To a solution of 360 mg (0.354 mmol) of the crude product in MeOH (7.5 mL) was added 1 N NaOH (3.54 mL, 3.54 mmol). After
15 stirring at 50°C for 90 min, the reaction mixture was quenched at room temperature with 1 N HCl (2.85 mL, 2.50 mmol). After stirring for 1 h at room temperature, the solid was collected to provide 229 mg of the title compound: partial ¹H-NMR (DMSO-d₆, 300 MHz) δ 9.41 (s, 2 H), 7.36 (s, 2 H), 7.17 (d, 2 H), 7.12 (d, 2 H), 4.78 (d, 2 H), 4.50 (d, 2 H), 4.22 (d, 2 H), 3.69 (d, 2 H), 2.67 (s, 4 H), and 2.18 ppm (s, 6
20 H).

Step 2**N,N'-Bis[2-methyl-5-(2,3,4,6-tetra-O-sulfato-β-D-glucopyranosyloxymethyl)phenyl]succinamide Octasodium Salt**

25 A solution of 229 mg (0.337 mmol) of N,N'-bis[2-methyl-5-(β-D-glucopyranosyloxymethyl)phenyl]succinamide and sulfur trioxide trimethylamine complex (2.11 g, 15.2 mmol) in DMF (30 mL) was stirred at 50°C overnight. The reaction mixture was quenched with H₂O (10 mL) and concentrated to an oily solid.
30 The solid was removed and rinsed with a very small amount of H₂O. The combined filtrates were concentrated and partially purified by repeated Sephadex G-10 chromatography (H₂O elution) and then by dialysis using a 500 MW cut off bag. A small amount of trimethylammonium sulfate was still seen by NMR. Cation exchange was effected with a column of Dowex 50 x 8 strongly acidic (Na form)
35 resin (H₂O elution) to provide 249 mg (49% yield) of the title compound as an off-white solid, mp >200°C: partial ¹H-NMR (D₂O, 400 MHz) δ 7.39 (d, 2 H), 7.37 (d,

- 44 -

2 H), and 4.55 ppm (t, 2 H); ^{13}C -NMR (D_2O , 100 MHz) δ 173.9, 134.82, 134.80, 134.3, 130.8, 127.6, 126.7, 98.8, 75.9, 75.5, 73.4, 72.4, 70.5, 67.8, 31.0, and 16.7 ppm; mass spectrum ((-) FAB) m/z 1472.6 ($\text{M}-\text{Na}$) $^-$, 1370.7 ($\text{m}-\text{Na}-\text{NaSO}_3+\text{H}$) $^-$, 765.9, and 564.8. Anal. Calcd. for $\text{C}_{32}\text{H}_{36}\text{N}_2\text{Na}_9\text{O}_{38}\text{S}_8 \cdot 2 \text{Na}_2\text{SO}_4 \cdot 6 \text{H}_2\text{O}$: C, 20.34; H, 2.54; N, 1.48. Found: C, 20.19; H, 2.22; N, 1.39.

EXAMPLE 26

Step 1

10 **N-[5-(Hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-3-nitrobenzamide**

To a stirred mixture of 5-(hepta-O-acetyl- β -maltosyloxymethyl)-2-methylphenylamine (1.90 g, 2.52 mmol) and pyridine (0.22 g, 2.77 mmol) in CH_2Cl_2 (10 mL) was added 3-nitrobenzoyl chloride (0.51 g, 2.77 mmol). After 18 h, the mixture was diluted with EtOAc, washed with sat. NaHCO_3 , H_2O , and brine, dried (MgSO_4), and concentrated. Purification by flash chromatography (1 : 1 EtOAc / hexane) gave 2.00 g (88%) of the title compound as a white foam. ^1H -NMR ($\text{DMSO}-d_6$, 400 MHz) δ 10.28 (s, 1 H), 8.80 (s, 1 H), 8.45 (dd, 1 H), 8.42 (d, 1 H), 7.84 (m, 1 H), 7.28 (d, 1 H), 7.25 (s, 1 H), 7.10 (d, 1 H), 5.30 (m, 2 H), 5.20 (t, 1 H), 5.05 (t, 1 H), 4.85 (d, 1 H), 4.80 (m, 1 H), 4.75 (m, 2 H), 4.56 (d, 1 H), 4.40 (dd, 1 H), 4.19 (m, 2 H), 4.0 (m, 4 H), 2.20 (s, 3 H), and 2.00 ppm (m, 21 H). Anal. Calcd. for $\text{C}_{41}\text{H}_{48}\text{N}_2\text{O}_{21}$: C, 54.42; H, 5.35; N, 3.10. Found: C, 54.30; H, 5.27; N, 3.10.

25

Step 2

N-[5-(β -D-Maltosyloxymethyl)-2-methylphenyl]-3-nitrobenzamide

To a stirred solution of N-[5-(hepta-O-acetyl- β -D-maltosyloxy)-2-methylphenyl]-3-nitrobenzamide (2.00 g, 2.21 mmol) in MeOH (20 mL) was added 25 wt% NaOMe in MeOH (5.10 mL, 22.10 mmol). After 3 h, 10 g of Amberlite IR-120 (H^+) ion exchange resin was added. The mixture was filtered and the filtrate was concentrated to give 1.30 g (96%) of the title compound as a white solid, mp 166-168°C: ^1H -NMR ($\text{DMSO}-d_6$, 400 MHz) δ 10.37 (s, 1 H), 8.80 (t, 1 H), 8.43 (m, 2 H), 7.85 (m, 1 H), 7.35 (s, 1 H), 7.25 (m, 2 H), 5.00 (d, 1 H), 4.85 (d, 1 H), 4.57 (d, 1

- 45 -

H), 4.30 (d, 1 H), 3.75 (m, 2 H), 3.60 (m, 2 H), 3.40 (m, 6 H), 3.10 (m, 2 H), and 2.21 ppm (s, 3 H); mass spectrum *m/e* 609 (M-H).

Step 3

5 **N-[5-(Hepta-O-sulfato- β -D-maltosyloxy)-2-methylphenyl]-3-nitrobenzamide**
Heptasodium Salt

A mixture of N-[5-(β -D-maltosyloxymethyl)-2-methylphenyl]-3-nitrobenzamide (1.27 g, 2.08 mmol) and sulfur trioxide trimethylamine complex (10.13 g, 72.79 mmol) in DMF (10 mL) was heated at 70 - 75°C for 4 days. The mixture was cooled, MeOH was added, and the mixture was filtered. The filtrate was concentrated, taken up in MeOH, and passed through a Sephadex LH-20-100 column (1 : 1 MeOH/CHCl₃; 0.1% Et₃N). The fractions were concentrated and passed through a Sephadex G-10 gel filtration column (H₂O) to give a brown oil. Further purification by reverse phase chromatography (C-18; H₂O), flash chromatography (5 : 0.1 : 0.5 CH₃CN/H₂O/Et₃N), and ion exchange on Sephadex SP C-25 (Na⁺) gave 1.10 g (40%) of the title compound as a white solid, mp 168 - 170°C: ¹H-NMR (D₂O, 400 MHz) δ 8.82 (t, 1 H), 8.52 (m, 1 H), 8.38 (m, 1 H), 7.86 (m, 1 H), 7.45, (s, 2 H), 5.57 (d, 1 H), 4.99 (d, 1 H), 4.95 (d, 1 H), 4.80 (m, 2 H), 4.62 (t, 1 H), 4.55 (s, 1 H), 4.46 (m, 1 H), 4.30 (m, 4 H), 4.18 (m, 1 H), 4.05 (m, 1 H), and 2.31 ppm (s, 3 H); mass spectrum *m/z* 1323. Anal. Calcd. for C₂₇H₂₇N₂Na₇O₃₅S₇•3H₂O: C, 23.52; H, 2.41; N, 2.03. Found: C, 22.70; H, 2.69; N, 1.72.

Step 4

25 **3-[N-[5-(Hepta-O-sulfato- β -D-maltosyloxy)-2-methylphenyl]phenylamine**
Heptasodium Salt

A solution of N-[5-(hepta-O-sulfato- β -D-maltosyloxy)-2-methylphenyl]-3-nitrobenzamide heptasodium salt (0.60 g, 0.45 mmol) in MeOH, H₂O, and pyridine was hydrogenated at atmospheric pressure over 10% Pd/C for 6 h. The catalyst was removed by filtration, and the filtrate was concentrated and passed through a Sephadex SP-C25 (Na⁺) ion exchange column to give 0.40 g (68%) of the title compound as a white solid, mp 232 - 234°C (dec): ¹H-NMR (D₂O, 300 MHz) δ 7.20 (m, 6 H), 6.93 (m, 1 H), 5.42 (d, 1 H), 4.75 (m, 2 H), 4.60 (m, 3 H), 4.48 (m, 2 H),

- 46 -

4.40 (dd, 2 H), 4.30 (t, 1 H), 4.15 (m, 2 H), 4.05 (m, 3 H), 3.95 (m, 2 H), and 2.15 ppm (s, 3 H).

Step 5

5 **3,3'-[N,N'-Ureidobis{[N-{2-methyl-5-(hepta-O-sulfato-β-D-malonyloxymethyl)phenyl}]benzamide Tetradecasodium Salt**

To a stirred mixture of 3-[N-[5-(hepta-O-sulfato-β-D-malonyloxy)-2-methylphenyl]]phenylamine heptasodium salt (440 mg, 0.34 mmol) and pyridine (5 mL) was added triphosgene (20 mg, 0.057 mmol). Stirring was continued at room temperature for 18 h. The mixture was concentrated, passed through a Sephadex G-10 gel filtration column, and a Sephadex SP-C25 (Na⁺) ion exchange column. The fractions were concentrated and triturated with MeOH to give 350 mg (79%) of the title compound as an off-white solid, mp 220°C (dec): ¹H-NMR (D₂O, 400 MHz) δ 7.61 (d, 2 H), 7.59 (s, 2 H), 7.50 (m, 2 H), 7.43 (m, 8 H), 7.29 (d, 2 H), 5.54 (d, 2 H), 4.95 (t, 4 H), 4.80 (m, 2 H), 4.61 (t, 2 H), 4.52 (dd, 2 H), 4.44 (t, 4 H), 4.30 (m, 12 H), 4.20 (m, 2 H), 3.98 (t, 2 H), and 2.28 ppm (s, 6 H); ¹³C-NMR (D₂O, 100 MHz) δ 169.8, 135.3, 135.1, 134.8, 134.4, 131.1, 130.0, 128.1, 126.9, 122.3, 121.7, 117.6, 94.7, 77.6, 76.6, 75.0, 73.7, 73.3, 73.1, 72.5, 69.8, 67.8, 66.0, and 16.8 ppm; mass spectrum *m/z* 1797. Anal. Calcd. for C₅₅H₅₆N₄Na₁₄O₆₇S₁₄•18H₂O: C, 22.47; H, 3.15; N, 1.91. Found: C, 22.11; H, 2.81; N, 1.59.

EXAMPLE 27**Step 1**

25 **N,N'-Bis{3-[2-methyl-5-(hepta-O-acetyl-β-D-malonyloxymethyl)phenyl]carbamoylphenyl}isophthalamide**

To a stirred mixture of 3-amino-[5-(hepta-O-acetyl-β-D-malonyloxymethyl)-2-methylphenyl]benzamide (1.0 g, 1.143 mmol) and triethylamine (0.12 g, 1.143 mmol) in CH₂Cl₂ (5 mL) was added isophthaloyl dichloride (0.12 g, 0.572 mmol). After 18 h, water was added and the layers were separated. The organic phase was washed with saturated aqueous NaHCO₃ and brine, dried (MgSO₄), and concentrated. Purification by flash chromatography gave 0.57 g (53%) of product as a white solid, mp 178 - 180 °C: ¹H-NMR (DMSO-*d*₆, 300 MHz) δ 10.60 (s, 2 H), 9.90 (s, 2 H),

- 47 -

8.60 (s, 1 H), 8.37 (s, 2 H), 8.21 (dd, J = 1.5, 7.7 Hz, 2 H), 8.05 (d, J = 7.7 Hz, 2 H), 7.75 (m, 3 H), 7.52 (t, J = 7.9 Hz, 2 H), 7.25 (m, 4 H), 7.10 (d, J = 7.8 Hz, 2 H), 5.30 (m, 5 H), 5.03 (m, 3 H), 4.80 (m, 4 H), 4.70 (m, 4 H), 4.50 (d, J = 12.5 Hz, 2 H), 4.40 (d, J = 12.5 Hz, 2 H), 4.20 (m, 4 H), 3.95 (m, 8 H), 2.20 (s, 6 H), and 1.90 - 2.00 ppm (m, 42 H).

Step 2

N,N'-Bis{3-[2-methyl-5-(β-D-maltosyloxymethyl)phenylcarbamoyl]phenyl}isophthalamide

To a warmed solution of N,N'-bis{3-[2-methyl-5-(hepta-O-acetyl-β-D-maltosyloxymethyl)phenylcarbamoyl]phenyl}isophthalamide (0.572 g, 0.304 mmol) in MeOH (10 mL) was added 25 wt% NaOMe in MeOH (0.5 mL, 2.13 mmol). After 2 h, Amberlite IR-120 (H⁺) resin was added. The mixture was filtered and concentrated to give 0.300 g (77%) of product as a white solid, mp 232-234°C: ¹H-NMR (DMSO-*d*₆, 300 MHz) δ 10.65 (s, 2 H), 9.90 (s, 2 H), 8.60 (s, 1 H), 8.35 (s, 2 H), 8.21 (dd, J = 1.5, 7.7 Hz, 2 H), 8.05 (d, J = 7.7 Hz, 2 H), 7.70 (m, 2 H), 7.50 (t, J = 7.9 Hz, 2 H), 7.35 (s, 2 H), 7.20 (m, 5 H), 5.01 (d, J = 3.9 Hz, 2 H), 4.80 (d, J = 12.5 Hz, 2 H), 4.50 (d, J = 12.5 Hz, 2 H), 4.30 (d, J = 7.9 Hz, 2 H), 3.20 - 3.75 (m, 26 H), 3.10 (m, 4 H), 2.20 (s, 6 H).


Step 3

N,N'-Bis{3-[2-methyl-5-(hepta-O-sulfato-β-D-maltosyloxy-methyl)phenylcarbamoyl]phenyl}isophthalamide Tetradecasodium Salt

A mixture of N,N'-bis{3-[2-methyl-5-(β-D-maltosyloxymethyl)-phenylcarbamoyl]phenyl}isophthalamide (0.30 g, 0.232 mmol) and sulfur trioxide pyridine complex (2.60 g, 16.267 mmol) in DMF (10 mL) was stirred at room temperature for 2 days. The mixture was concentrated, purified on a Sephadex LH-20-100 column (0.5% Et₃N/DMF), and converted to a sodium salt with Sephadex SP-C-25 ion exchange resin to give 0.200 g (31%) of product as an off white solid, mp 222°C (dec): ¹H-NMR (D₂O, 400 MHz) δ 8.45 (s, 1 H), 8.35 (brs, 2 H), 8.10 (brs, 2 H), 7.95 (d, J = 7.9 Hz, 2 H), 7.85 (d, 7.9 Hz, 2 H), 7.75 (brs, 2 H), 7.57 (brs, 2 H), 7.35 (brs, 5 H), 4.75 (m, 4 H), 4.45 (m, 4 H), 4.30 (m, 4 H), 4.10 (m, 4 H), 3.80 (m, 4 H), 3.57 (m, 4 H), 3.28 (m, 8 H), and 2.20 ppm (s, 6 H); ¹³C-NMR (D₂O, 100 MHz) δ 160, 137, 134, 130, 128, 120, 102, 96, 75, 74, 72, 62, 56, 49, 18 ppm.

We claim:

1. A compound of formula I




5


I

wherein

each of R¹, R², R³, and R⁴ are, independently, H, SO₃M, or a sugar group having the structure:



- 10 and each oligosaccharide group of the structure



contains from 1 to 3 sugar groups;


M is lithium, sodium, potassium, or ammonium;

n is 1 or 2;

- 15 X is hydrogen, halogen, lower alkyl having 1 to 6 carbon atoms, or lower alkoxy having 1 to 6 carbon atoms;


Y is carbonyl or sulfonyl;

Z is alkyl having from 1 to 12 carbon atoms,



and X is as defined above;
 or a pharmaceutically acceptable salt thereof.


5 2. A compound according to claim 1 of formula I




I

wherein

10 each of R¹, R², R³, and R⁴ are, independently, H, SO₃M, or



and each oligosaccharide group of the structure



contains 1 or 2 sugar groups;

- 50 -


M is lithium, sodium, potassium, or ammonium;

n is 1 or 2;

X is hydrogen, halogen, lower alkyl having 1 to 6 carbon atoms, or lower alkoxy having 1 to 6 carbon atoms;

5 Y is carbonyl or sulfonyl;

Z is alkyl having from 1 to 12 carbon atoms,



or a pharmaceutically acceptable salt thereof.

10 3. A compound according to claim 2 which is dodecanedioic acid bis{[2-methyl-5-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]amide} tetradecasodium salt or a pharmaceutically acceptable salt thereof.

15 4. A compound according to claim 2 which is 2 N,N'-bis[5-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)-2-methylphenyl]-terephthalamide tetradecasodium salt or a pharmaceutically acceptable salt thereof.

20 5. A compound according to claim 2 which is biphenyl-4,4'-dicarboxylic acid bis{[5-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)-2-methylphenyl]amide} tetradecasodium salt or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 2 which is N,N'-bis[5-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)-2-methylphenyl]isophthalamide tetradecasodium salt; or a pharmaceutically acceptable salt thereof.

25 7. A compound according to claim 2 which is decanedioic acid bis{[3,5-bis(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]amide} octacosasodium salt or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 2 which is biphenyl-4,4'-dicarboxylic acid bis{[3,5-bis(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]amide} octacosasodium salt or a pharmaceutically acceptable salt thereof.
- 5 9. A compound according to claim 2 which is biphenyl-4,4'-dicarboxylic acid bis{[3,5-bis-(hepta-O-sulfato- β -D-lactosyloxymethyl)phenyl]amide} octacosasodium salt or a pharmaceutically acceptable salt thereof.
- 10 10. A compound according to claim 2 which is biphenyl-4,4'-dicarboxylic acid bis{[3,5-(bis-(hepta-O-sulfato- β -D-maltosyloxymethyl)phenyl]amide} octacosasodium salt or a pharmaceutically acceptable salt thereof.
- 15 11. A compound according to claim 2 which is biphenyl-4,4'-dicarboxylic acid bis{[3,5-bis-(tetra-O-sulfato- β -D-glucosyloxymethyl)phenyl]amide} hexadecasodium salt or a pharmaceutically acceptable salt thereof.
- 20 12. A compound according to claim 2 which is biphenyl-4,4'-dicarboxylic acid bis{[2-chloro-5-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]amide} tetradecasodium salt or a pharmaceutically acceptable salt thereof.
- 25 13. A compound according to claim 2 which is biphenyl-4,4'-dicarboxylic acid bis{[4-chloro-2-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]amide} tetradecasodium salt or a pharmaceutically acceptable salt thereof.
- 30 14. A compound according to claim 2 which is N,N'-bis[3,5-bis(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]succinamide octacosasodium salt or a pharmaceutically acceptable salt thereof.
- 35 15. A compound according to claim 2 which is N,N'-bis[3,5-bis(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]terephthalamide octacosasodium salt or a pharmaceutically acceptable salt thereof.
16. A compound according to claim 2 which is biphenyl-4,4'-disulfonic acid bis{[2-methyl-5-(hepta-O-sulfato- β -D-cellobiosyloxymethyl)phenyl]amide} tetradecasodium salt or a pharmaceutically acceptable salt thereof.

- 52 -

17. A compound according to claim 2 which is N,N'-bis[2-methyl-5-(2,3,4,6-tetra-O-sulfato-β-D-glucopyranosyloxymethyl)phenyl]succinamide octasodium salt or a pharmaceutically acceptable salt thereof.


5 18. A compound according to claim 2 which is 3,3'-[1,3-ureido]-bis{N-[2-methyl-5-(hepta-O-sulfato-β-D-maltosyloxymethyl)phenyl]}benzamide tetradecasodium salt or a pharmaceutically acceptable salt thereof.

10 19. A compound according to claim 2 which is 3,3'-(N,N'-ureido)bis-({N-[2-chloro-5-(hepta-O-sulfato-β-D-cellobiosyloxymethyl)phenyl]}benzamide) tetradecasodium salt or a pharmaceutically acceptable salt thereof.

15 20. A compound according to claim 2 which is N,N'-bis(3-[2-methyl-5-(hepta-O-sulfato-β-D-maltosyloxymethyl)phenyl]isophthalamide) tetradecasodium salt or a pharmaceutically acceptable salt thereof.

21. A method of treating a human suffering from a condition which is characterized by excessive smooth muscle proliferation, the method comprising administering to the human an effective amount of the compound of the formula I


20



wherein


each of R¹, R², R³, and R⁴ are, independently, H, SO₃M, or a sugar group

25 having the structure:



and each oligosaccharide group of the structure

- 53 -



contains from 1 to 3 sugar groups;



M is lithium, sodium, potassium, or ammonium;

n is 1 or 2;

5 X is a hydrogen, halogen, lower alkyl having 1 to 6 carbon atoms, or lower alkoxy having 1 to 6 carbon atoms;

Y is carbonyl or sulfonyl;

Z is alkyl having from 1 to 12 carbon atoms,




10 and X is as defined above;
or a pharmaceutically acceptable salt thereof.

22. The use of Claim 21 wherein the disease or condition which is characterized by excessive smooth muscle proliferation is restenosis

15

23. A pharmaceutical composition comprising an effective amount of a compound of formula I




20


I

wherein

each of R¹, R², R³, and R⁴ are, independently, H, SO₃M, or a sugar group having the structure:



5 and each oligosaccharide group of the structure



contains from 1 to 3 sugar groups;



M is lithium, sodium, potassium, or ammonium;

n is 1 or 2;

10 X is a hydrogen, halogen, lower alkyl having 1 to 6 carbon atoms, or lower alkoxy having 1 to 6 carbon atoms;

Y is carbonyl or sulfonyl;

Z is alkyl having from 1 to 12 carbon atoms,




15 and X is as defined above;

or a pharmaceutically acceptable salt thereof.

24. The use, to treat a human suffering from a condition which is characterized by excessive smooth muscle proliferation, of an effective amount of the compound of formula I


20




I

wherein

each of R¹, R², R³, and R⁴ are, independently, H, SO₃M, or a sugar group
 5 having the structure:



and each oligosaccharide group of the structure



contains from 1 to 3 sugar groups;


10 M is lithium, sodium, potassium, or ammonium;

n is 1 or 2;

X is a hydrogen, halogen, lower alkyl having 1 to 6 carbon atoms, or lower
 alkoxy having 1 to 6 carbon atoms;

Y is carbonyl or sulfonyl;


15 Z is alkyl having from 1 to 12 carbon atoms,



- 56 -


and X is as defined above;
or a pharmaceutically acceptable salt thereof.

25. The use, in the manufacture of a medicament to treat a human
5 suffering from a condition which is characterized by excessive smooth muscle
proliferation, of an effective amount of the compound of formula I




10 wherein

each of R¹, R², R³, and R⁴ are, independently, H, SO₃M, or a sugar group
having the structure:



and each oligosaccharide group of the structure



15

contains from 1 to 3 sugar groups;

M is lithium, sodium, potassium, or ammonium;


n is 1 or 2;

X is a hydrogen, halogen, lower alkyl having 1 to 6 carbon atoms, or lower
20 alkoxy having 1 to 6 carbon atoms;

Y is carbonyl or sulfonyl;

Z is alkyl having from 1 to 12 carbon atoms,

- 57 -



and X is as defined above;

or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

Intern: al Application No
PCT/US 95/14686

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07H15/203 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07H A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CARBOHYDRATE RESEARCH, vol. 151, 15 August 1986, AMSTERDAM NL, pages 371-378, XP000565755 U. ZEHAVI & M. HERCHMAN: "Probing acceptor specificity in the glycogen synthase reaction with polymer-bound oligosaccharides." see page 373 ---	1
A	US,A,4 431 637 (UPESLACIS JANIS ET AL) 14 February 1984 see column 4 ---	1
A	WO,A,90 06755 (GLYCOMED INC) 28 June 1990 see the whole document ---	1.21, 23-25
-/--		

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

- * Special categories of cited documents:
- * "A" document defining the general state of the art which is not considered to be of particular relevance
 - * "B" earlier document but published on or after the international filing date
 - * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 - * "G" document referring to an oral disclosure, use, exhibition or other means
 - * "P" document published prior to the international filing date but later than the priority date claimed
 - * "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 - * "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 - * "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 - * "E" document member of the same patent family

Date of the actual completion of the international search 17 April 1996	Date of mailing of the international search report
---	--

Name and mailing address of the ISA European Patent Office, P.O. 5818 Patentplan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epu nl, Fax (+ 31-70) 340-3016	Authorized officer Moreno, C
---	--

INTERNATIONAL SEARCH REPORT

Internat'l Application No
PCT/US 95/14686

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 356 275 (SANOFI SA) 28 February 1990 see the whole document ---	1,21, 23-25
A	EP,A,0 454 220 (AKZO NV ;SANOFI SA (FR)) 30 October 1991 see the whole document -----	1,21, 23-25

1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/14686

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 21 and 22
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 21 and 22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the proscribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

 The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 95/14686

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4431637	14-02-84	NONE	
-----	-----	-----	-----
WO-A-9006755	28-06-90	US-A- 5032679	16-07-91
		AU-B- 634199	18-02-93
		AU-B- 4827490	10-07-90
		CA-A- 2005739	15-06-90
		EP-A- 0448637	02-10-91
		JP-T- 4503950	16-07-92
		US-A- 5380716	10-01-95
-----	-----	-----	-----
EP-A-0356275	28-02-90	FR-A- 2634485	26-01-90
		AT-T- 108804	15-08-94
		AU-B- 620632	20-02-92
		AU-B- 3885689	25-01-90
		DE-D- 68916878	25-08-94
		DE-T- 68916878	16-03-95
		ES-T- 2056239	01-10-94
		JP-A- 2073801	13-03-90
		QA-A- 9125	31-10-91
		PT-B- 91249	04-05-95
		SU-A- 1831487	30-07-93
-----	-----	-----	-----
EP-A-0454220	30-10-91	AU-B- 7525591	24-10-91
		CA-A- 2040905	24-10-91
		DE-T- 69100275	02-12-93
		ES-T- 2060284	16-11-94
		IL-A- 97904	31-07-95
		US-A- 5382570	17-01-95
		US-A- 5378829	03-01-95
-----	-----	-----	-----